UNITED STATES Washington, D.C. 20549 | OMB APPROVAL | |
OMB Number: 3235-0582 | ||
Expires: July 31, 2024 | ||
Estimated average burden | ||
hours per response........4 |
FORM N-PX
ANNUAL REPORT OF PROXY VOTING RECORD OF REGISTERED
MANAGEMENT INVESTMENT COMPANY
Investment Company Act file number 811- 04889
Tekla Healthcare Investors
(Exact name of registrant as specified in charter)
100 Federal Street, 19th Floor, Boston, MA | 02110 | |
(Address of principal executive offices) | (Zip code) |
Laura Woodward
Tekla Healthcare Investors
100 Federal Street, 19th Floor, Boston MA 02110
(Name and address of agent for service)
Registrant’s telephone number, including area code: 617-772-8500
Date of fiscal year end: September 30
Date of reporting period: 7/1/21-6/30/22
Form N-PX is to be used by a registered management investment company, other than a small business investment company registered on Form N-5 (ss.ss. 239.24 and 274.5 of this chapter), to file reports with the Commission, not later than August 31 of each year, containing the registrant’s proxy voting record for the most recent twelve-month period ended June 30, pursuant to section 30 of the Investment Company Act of 1940 and rule 30b1-4 thereunder (17 CFR 270.30b1-4). The Commission may use the information provided on Form N-PX in its regulatory, disclosure review, inspection, and policymaking roles.
A registrant is required to disclose the information specified by Form N-PX, and the Commission will make this information public. A registrant is not required to respond to the collection of information contained in Form N-PX unless the Form displays a currently valid Office of Management and Budget (“OMB”) control number. Please direct comments concerning the accuracy of the information collection burden estimate and any suggestions for reducing the burden to the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW, Washington, DC 20549-0609. The OMB has reviewed this collection of information under the clearance requirements of 44 U.S.C. ss. 3507.
Item 1. Proxy Voting Record.
Vote Summary
ABBOTT LABORATORIES
Security | 002824100 | Meeting Type | Annual |
Ticker Symbol | ABT | Meeting Date | 29-Apr-2022 |
Record Date | 02-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1. | R. J. Alpern | For | For | |||||||
2. | S. E. Blount | For | For | |||||||
3. | R. B. Ford | For | For | |||||||
4. | P. Gonzalez | For | For | |||||||
5. | M. A. Kumbier | For | For | |||||||
6. | D. W. McDew | For | For | |||||||
7. | N. McKinstry | For | For | |||||||
8. | W. A. Osborn | For | For | |||||||
9. | M. F. Roman | For | For | |||||||
10. | D. J. Starks | For | For | |||||||
11. | J. G. Stratton | For | For | |||||||
12. | G. F. Tilton | For | For | |||||||
2. | Ratification of Ernst & Young LLP As Auditors | Management | For | For | ||||||
3. | Say on Pay - An Advisory Vote on the Approval of Executive Compensation | Management | For | For | ||||||
4. | Shareholder Proposal - Special Shareholder Meeting Threshold | Shareholder | Against | For | ||||||
5. | Shareholder Proposal - Independent Board Chairman | Shareholder | For | Against | ||||||
6. | Shareholder Proposal - Rule 10b5-1 Plans | Shareholder | Against | For | ||||||
7. | Shareholder Proposal - Lobbying Disclosure | Shareholder | Against | For | ||||||
8. | Shareholder Proposal - Antimicrobial Resistance Report | Shareholder | Against | For |
ABBVIE, INC.
Security | 00287Y109 | Meeting Type | Annual |
Ticker Symbol | ABBV | Meeting Date | 06-May-2022 |
Record Date | 07-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1. | William H.L. Burnside | For | For | |||||||
2. | Thomas C. Freyman | For | For | |||||||
3. | Brett J. Hart | For | For | |||||||
4. | Edward J. Rapp | For | For | |||||||
2. | Ratification of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2022 | Management | For | For | ||||||
3. | Say on Pay - An advisory vote on the approval of executive compensation | Management | For | For | ||||||
4. | Approval of a management proposal regarding amendment of the certificate of incorporation to eliminate supermajority voting | Management | For | For | ||||||
5. | Stockholder Proposal - to Adopt a Policy to Require Independent Chairman | Shareholder | For | Against | ||||||
6. | Stockholder Proposal - to Seek Shareholder Approval of Certain Termination Pay Arrangements | Shareholder | Against | For | ||||||
7. | Stockholder Proposal - to Issue a Report on Board Oversight of Competition Practices | Shareholder | Against | For | ||||||
8. | Stockholder Proposal - to Issue an Annual Report on Political Spending | Shareholder | Against | For |
ADAPTIVE BIOTECHNOLOGIES CORPORATION
Security | 00650F109 | Meeting Type | Annual |
Ticker Symbol | ADPT | Meeting Date | 10-Jun-2022 |
Record Date | 14-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1.1 | Election of Class III Director for a three-year term expiring at the 2025 annual meeting: Chad Robins | Management | For | For | |||||
1.2 | Election of Class III Director for a three-year term expiring at the 2025 annual meeting: Kevin Conroy | Management | For | For | |||||
1.3 | Election of Class III Director for a three-year term expiring at the 2025 annual meeting: Dr. Michael Pellini | Management | For | For | |||||
2. | To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in the proxy statement. | Management | For | For | |||||
3. | To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our year ending December 31, 2022. | Management | For | For |
ADDUS HOMECARE CORPORATION
Security | 006739106 | Meeting Type | Annual |
Ticker Symbol | ADUS | Meeting Date | 15-Jun-2022 |
Record Date | 22-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1. | Esteban López, M.D. | For | For | |||||||
2. | Jean Rush | For | For | |||||||
3. | Susan T. Weaver MD FACP | For | For | |||||||
2. | To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as our independent auditor for the fiscal year ending December 31, 2022. | Management | For | For | ||||||
3. | To approve, on an advisory, non-binding basis, the compensation of the named executive officers. | Management | For | For |
AFFIMED N.V
Security | N01045108 | Meeting Type | Annual |
Ticker Symbol | AFMD | Meeting Date | 22-Jun-2022 |
Record Date | 25-May-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
3. | Adoption of the Statutory Annual Accounts for the financial year 2021 | Management | For | For | |||||
4. | Discharge of the managing directors for their management during the financial year 2021 | Management | For | For | |||||
5. | Discharge of the supervisory directors for their supervision during the financial year 2021 | Management | For | For | |||||
6b. | Amendment of the Remuneration Policy for the Management Board | Management | For | For | |||||
6c. | Amendment of the Remuneration Policy for the Supervisory Board | Management | For | For | |||||
7. | Reappointment of Dr. Bernhard Ehmer as a supervisory director | Management | For | For | |||||
8. | Appointment of the auditor for the financial year 2022 | Management | For | For | |||||
9. | Authorization to acquire shares | Management | For | For |
ALIGN TECHNOLOGY, INC.
Security | 016255101 | Meeting Type | Annual |
Ticker Symbol | ALGN | Meeting Date | 18-May-2022 |
Record Date | 23-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director: Kevin J. Dallas | Management | For | For | |||||
1b. | Election of Director: Joseph M. Hogan | Management | For | For | |||||
1c. | Election of Director: Joseph Lacob | Management | For | For | |||||
1d. | Election of Director: C. Raymond Larkin, Jr. | Management | For | For | |||||
1e. | Election of Director: George J. Morrow | Management | For | For | |||||
1f. | Election of Director: Anne M. Myong | Management | For | For | |||||
1g. | Election of Director: Andrea L. Saia | Management | For | For | |||||
1h. | Election of Director: Greg J. Santora | Management | For | For | |||||
1i. | Election of Director: Susan E. Siegel | Management | For | For | |||||
1j. | Election of Director: Warren S. Thaler | Management | For | For | |||||
2. | RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS: Proposal to ratify the appointment of PricewaterhouseCoopers LLP as Align Technology, Inc.’s independent registered public accountants for the fiscal year ending December 31, 2022. | Management | For | For | |||||
3. | ADVISORY VOTE ON NAMED EXECUTIVES COMPENSATION: Consider an Advisory Vote to Approve the Compensation of our Named Executive Officers. | Management | For | For |
ALKERMES PLC
Security | G01767105 | Meeting Type | Special |
Ticker Symbol | ALKS | Meeting Date | 13-May-2022 |
Record Date | 13-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | To approve certain amendments to the Company’s Articles of Association to provide for plurality voting for contested elections. | Management | For | For |
ALKERMES PLC
Security | G01767105 | Meeting Type | Annual |
Ticker Symbol | ALKS | Meeting Date | 07-Jul-2022 |
Record Date | 01-Jun-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Class II Director: Emily Peterson Alva | Management | For | For | |||||
1B. | Election of Class II Director: Cato T. Laurencin, M.D., Ph.D. | Management | For | For | |||||
1C. | Election of Class II Director: Brian P. McKeon | Management | For | For | |||||
1D. | Election of Class II Director: Christopher I. Wright M.D., PH.D. | Management | For | For | |||||
2. | To approve, in a non-binding, advisory vote, the compensation of the Company’s named executive officers. | Management | For | For | |||||
3. | To ratify, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the independent auditor and accounting firm of the Company and to authorize, in a binding vote, the Audit and Risk Committee of the Board to set the independent auditor and accounting firm’s remuneration. | Management | For | For | |||||
4. | To approve the Alkermes plc 2018 Stock Option and Incentive Plan, as amended. | Management | For | For | |||||
5. | To renew Board authority to allot and issue shares under Irish law. | Management | For | For | |||||
6. | To renew Board authority to disapply the statutory pre- emption rights that would otherwise apply under Irish law. | Management | For | For |
ALNYLAM PHARMACEUTICALS, INC.
Security | 02043Q107 | Meeting Type | Annual |
Ticker Symbol | ALNY | Meeting Date | 18-May-2022 |
Record Date | 28-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Class III Director: Margaret A. Hamburg, M.D. | Management | For | For | |||||
1B. | Election of Class III Director: Colleen F. Reitan | Management | For | For | |||||
1C. | Election of Class III Director: Amy W. Schulman | Management | For | For | |||||
2. | To approve the amended and restated 2018 Stock Incentive Plan. | Management | For | For | |||||
3. | To approve, in a non-binding advisory vote, the compensation of Alnylam’s named executive officers. | Management | For | For | |||||
4. | To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam’s independent auditors for the fiscal year ending December 31, 2022. | Management | For | For |
ALTIMMUNE, INC.
Security | 02155H200 | Meeting Type | Annual |
Ticker Symbol | ALT | Meeting Date | 23-Sep-2021 |
Record Date | 10-Aug-2021 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1. | Mitchel Sayare, Ph.D. | For | For | |||||||
2. | Vipin K. Garg, Ph.D. | For | For | |||||||
3. | David J. Drutz, M.D. | For | For | |||||||
4. | John M. Gill | For | For | |||||||
5. | Philip L. Hodges | For | For | |||||||
6. | Diane Jorkasky, M.D. | For | For | |||||||
7. | Wayne Pisano | For | For | |||||||
8. | Klaus O. Schafer MD MPH | For | For | |||||||
2. | Vote to ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2021. | Management | For | For | ||||||
3. | Hold an advisory vote on the compensation of the Company’s named executive officers as disclosed in the attached Proxy Statement. | Management | Against | Against | ||||||
4. | Approve the authorization to adjourn the Annual Meeting, if necessary or appropriate, to solicit additional proxies in favor of the foregoing proposals if there are not sufficient votes to approve the proposals. | Management | Against | Against |
AMGEN, INC.
Security | 031162100 | Meeting Type | Annual |
Ticker Symbol | AMGN | Meeting Date | 17-May-2022 |
Record Date | 18-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Director for a term of expiring at the 2023 annual meeting: Dr. Wanda M. Austin | Management | For | For | |||||
1B. | Election of Director for a term of expiring at the 2023 annual meeting: Mr. Robert A. Bradway | Management | For | For | |||||
1C. | Election of Director for a term of expiring at the 2023 annual meeting: Dr. Brian J. Druker | Management | For | For | |||||
1D. | Election of Director for a term of expiring at the 2023 annual meeting: Mr. Robert A. Eckert | Management | For | For | |||||
1E. | Election of Director for a term of expiring at the 2023 annual meeting: Mr. Greg C. Garland | Management | For | For | |||||
1F. | Election of Director for a term of expiring at the 2023 annual meeting: Mr. Charles M. Holley, Jr. | Management | For | For | |||||
1G. | Election of Director for a term of expiring at the 2023 annual meeting: Dr. S. Omar Ishrak | Management | For | For | |||||
1H. | Election of Director for a term of expiring at the 2023 annual meeting: Dr. Tyler Jacks | Management | For | For | |||||
1I. | Election of Director for a term of expiring at the 2023 annual meeting: Ms. Ellen J. Kullman | Management | For | For | |||||
1J. | Election of Director for a term of expiring at the 2023 annual meeting: Ms. Amy E. Miles | Management | For | For | |||||
1K. | Election of Director for a term of expiring at the 2023 annual meeting: Dr. Ronald D. Sugar | Management | For | For | |||||
1L. | Election of Director for a term of expiring at the 2023 annual meeting: Dr. R. Sanders Williams | Management | For | For | |||||
2. | Advisory vote to approve our executive compensation. | Management | For | For | |||||
3. | To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2022. | Management | For | For |
AMN HEALTHCARE SERVICES, INC.
Security | 001744101 | Meeting Type | Annual |
Ticker Symbol | AMN | Meeting Date | 06-May-2022 |
Record Date | 14-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Director: Jorge A. Caballero | Management | For | For | |||||
1B. | Election of Director: Mark G. Foletta | Management | For | For | |||||
1C. | Election of Director: Teri G. Fontenot | Management | For | For | |||||
1D. | Election of Director: R. Jeffrey Harris | Management | For | For | |||||
1E. | Election of Director: Daphne E. Jones | Management | For | For | |||||
1F. | Election of Director: Martha H. Marsh | Management | For | For | |||||
1G. | Election of Director: Susan R. Salka | Management | For | For | |||||
1H. | Election of Director: Sylvia Trent-Adams | Management | For | For | |||||
1I. | Election of Director: Douglas D. Wheat | Management | For | For | |||||
2. | To approve, by non-binding advisory vote, the compensation of the Company’s named executive officers. | Management | For | For | |||||
3. | To approve the AMN Healthcare Employee Stock Purchase Plan. | Management | For | For | |||||
4. | To ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. | Management | For | For | |||||
5. | A shareholder proposal entitled: “Special Shareholder Meeting Improvement”. | Shareholder | Against | For |
AMPHIVENA THERAPEUTICS, INC.
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 25-Aug-2021 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Approval of Bridge Financing; Waiver of Protective Provisions and Right of First Offer | Management | For | For |
AMPHIVENA THERAPEUTICS, INC.
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 08-Oct-2021 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Consent to Wind-down and Dissolution by the Stockholders | Management | For | For | |||||
2. | Enabling Power | Management | For | For |
AMPHIVENA THERAPEUTICS, INC.
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 14-Feb-2022 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | General Assignment for benefit of creditors | Management | For | For | |||||
2. | Voluntary dissolution of the company | Management | For | For |
ANTHEM, INC.
Security | 036752103 | Meeting Type | Annual |
Ticker Symbol | ANTM | Meeting Date | 18-May-2022 |
Record Date | 17-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1.1 | Election of Director: Susan D. DeVore | Management | For | For | |||||
1.2 | Election of Director: Bahija Jallal | Management | For | For | |||||
1.3 | Election of Director: Ryan M. Schneider | Management | For | For | |||||
1.4 | Election of Director: Elizabeth E. Tallett | Management | For | For | |||||
2. | Advisory vote to approve the compensation of our named executive officers. | Management | For | For | |||||
3. | To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2022. | Management | For | For | |||||
4. | To approve an amendment to our Articles of Incorporation to change our name to Elevance Health, Inc. | Management | For | For | |||||
5. | Shareholder proposal to prohibit political funding. | Shareholder | Against | For | |||||
6. | Shareholder proposal requesting a racial impact audit and report. | Shareholder | Against | For |
APELLIS PHARMACEUTICAL,S INC.
Security | 03753U106 | Meeting Type | Annual |
Ticker Symbol | APLS | Meeting Date | 01-Jun-2022 |
Record Date | 05-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1.1 | Election of Class II Director to hold office until the 2025 annual meeting: A. Sinclair Dunlop | Management | For | For | |||||
1.2 | Election of Class II Director to hold office until the 2025 annual meeting: Alec Machiels | Management | For | For | |||||
2. | To ratify the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. | Management | For | For | |||||
3. | To approve an advisory vote on executive compensation. | Management | For | For |
ARCUTIS BIOTHERAPEUTICS, INC.
Security | 03969K108 | Meeting Type | Annual |
Ticker Symbol | ARQT | Meeting Date | 01-Jun-2022 |
Record Date | 04-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Class II Director to hold office until the 2025 Annual Meeting: Bhaskar Chaudhuri, Ph.D. | Management | For | For | |||||
1b. | Election of Class II Director to hold office until the 2025 Annual Meeting: Howard Welgus, M.D. | Management | For | For | |||||
1c. | Election of Class II Director to hold office until the 2025 Annual Meeting: Sue-Jean Lin | Management | For | For | |||||
2. | To ratify the selection, by the Audit Committee of the Company’s Board of Directors, of Ernst & Young LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022. | Management | For | For | |||||
3. | To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers. | Management | For | For | |||||
4. | To approve, on a non-binding advisory basis, the frequency of future advisory votes on the compensation of the Company’s named executive officers. | Management | 1 Year | For |
ARENA PHARMACEUTICALS, INC.
Security | 040047607 | Meeting Type | Special |
Ticker Symbol | ARNA | Meeting Date | 02-Feb-2022 |
Record Date | 30-Dec-2021 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | To adopt the Agreement and Plan of Merger, dated December 12, 2021 (the “Merger Agreement”), by and among Arena Pharmaceuticals, Inc. (“Arena”), Pfizer Inc., and Antioch Merger Sub, Inc. | Management | For | For | |||||
2. | To approve, on an advisory (non-binding) basis, the compensation that may be paid or become payable to Arena’s named executive officers that is based on or otherwise relates to the Merger Agreement and the transactions contemplated by the Merger Agreement. | Management | For | For | |||||
3. | To adjourn the Special Meeting to a later date or dates if necessary or appropriate to solicit additional proxies if there are insufficient votes to adopt the Merger Agreement at the time of the Special Meeting. | Management | For | For |
ARGENX SE
Security | 04016X101 | Meeting Type | Annual |
Ticker Symbol | ARGX | Meeting Date | 10-May-2022 |
Record Date | 20-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
3. | Advisory vote to approve the 2021 remuneration report | Management | For | ||||||
4b. | Adoption of the 2021 annual accounts | Management | For | ||||||
4d. | Allocation of losses of the Company in the financial year 2021 to the retained earnings of the Company | Management | For | ||||||
4e. | Proposal to release the members of the board of directors from liability for their respective duties carried out in the financial year 2021 | Management | For | ||||||
5. | Re-appointment of Tim Van Hauwermeiren as executive director to the board of directors of the Company for a term of 4 years | Management | For | ||||||
6. | Re-appointment of Peter Verhaeghe as non-executive director to the board of directors of the Company for a term of 2 years | Management | For | ||||||
7. | Re-appointment of James Daly as non-executive director to the board of directors of the Company for a term of 4 years | Management | For | ||||||
8. | Re-appointment of Werner Lanthaler as non-executive director to the board of directors of the Company for a term of 2 years | Management | For | ||||||
9. | Authorization of the board of directors to issue shares and grant rights to subscribe for shares in the share capital of the Company up to a maximum of 10% of the outstanding capital at the date of the general meeting, for a period of 18 months from the annual general meeting and to limit or exclude statutory pre-emptive rights, if any. | Management | For | ||||||
10. | Amendment of the articles of association of argenx SE to align with current Dutch law and practice and to grant proxy to each of the directors of the Company and employees of Freshfields Bruckhaus Deringer LLP in having the deed of amendment executed | Management | For | ||||||
11. | Appointment of Deloitte Accountants B.V. as statutory auditor for the 2022 financial year. | Management | For |
ARKUDA THERAPEUTICS, INC.
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 16-Jul-2021 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
2. | Waiver of the need to satisfy the applicable Milestones associated with the Third Tranche Closing. | Management | For | For |
ARKUDA THERAPEUTICS, INC.
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 25-Jan-2022 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Amended and Restated Certificate of Incorporation. | Management | For | For | |||||
2. | Sale and Issuance of Series B Preferred Stock. | Management | For | For | |||||
3. | Restated By Laws. | Management | For | For | |||||
4. | Idemnification Agreement. | Management | For | For | |||||
5. | Amendment No.2 to the 2018 Stock Option and Grant Plan. | Management | For | For | |||||
6. | Waiver of Premptive Rights and Anti-Dillution Rights. | Management | For | For | |||||
7. | General Resolutions. | Management | For | For |
ARROWHEAD PHARMACEUTICALS, INC.
Security | 04280A100 | Meeting Type | Annual |
Ticker Symbol | ARWR | Meeting Date | 17-Mar-2022 |
Record Date | 21-Jan-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Director: Douglass Given | Management | For | For | |||||
1B. | Election of Director: Michael S. Perry | Management | For | For | |||||
1C. | Election of Director: Christopher Anzalone | Management | For | For | |||||
1D. | Election of Director: Marianne De Backer | Management | For | For | |||||
1E. | Election of Director: Mauro Ferrari | Management | For | For | |||||
1F. | Election of Director: Adeoye Olukotun | Management | For | For | |||||
1G. | Election of Director: William Waddill | Management | For | For | |||||
2. | To approve, in an advisory (non-binding) vote, the compensation paid to the Company’s named executive officers, as disclosed pursuant to Item 402 of Regulation S-K, including the compensation tables and narrative discussion. | Management | For | For | |||||
3. | To approve the Arrowhead Pharmaceuticals, Inc. Non- Employee Director Compensation Plan. | Management | For | For | |||||
4. | To ratify the selection of Rose, Snyder & Jacobs LLP as independent auditors of the Company for the fiscal year ending September 30, 2022. | Management | For | For |
ARVINAS, INC.
Security | 04335A105 | Meeting Type | Annual |
Ticker Symbol | ARVN | Meeting Date | 16-Jun-2022 |
Record Date | 19-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1. | Linda Bain | For | For | |||||||
2. | John Houston, Ph.D. | For | For | |||||||
3. | Laurie S. Alsup, M.D. | For | For | |||||||
2. | To approve, on an advisory basis, the Company’s executive compensation. | Management | For | For | ||||||
3. | Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. | Management | For | For |
ASCENDIS PHARMA A S
Security | 04351P101 | Meeting Type | Special |
Ticker Symbol | ASND | Meeting Date | 05-Nov-2021 |
Record Date | 21-Oct-2021 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | The Board of Directors proposes that attorney-at-law Lars Lüthjohan Jensen is elected as chairman of the general meeting. | Management | For | For | |||||
2. | Election of Director: Nominees for Class I, with a term expiring at the annual general meeting to be held in 2023: James I. Healy, Jan Møller Mikkelsen, Lisa Morrison; Nominees for Class II, with a term expiring at the annual general meeting to be held in 2022: Albert Cha, Lars Holtug, Rafaèle Tordjman | Management | For | For | |||||
3. | Authorisation of the chairman of the meeting: The Board of Directors proposes that Rafaèle Tordjman is elected. | Management | For | For |
ASCENDIS PHARMA A S
Security | 04351P101 | Meeting Type | Special |
Ticker Symbol | ASND | Meeting Date | 18-Nov-2021 |
Record Date | 21-Oct-2021 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Elect Lars Lüthjohan Jensen as chairman of the meeting | Management | For | For | |||||
2. | Elect Rafaèle Tordjman to the board | Management | For | For | |||||
3. | Authorize the chairman of the meeting to register Rafaèle Tordjman with the Danish Business Authority, if elected | Management | For | For |
ASCENDIS PHARMA A S
Security | 04351P101 | Meeting Type | Annual |
Ticker Symbol | ASND | Meeting Date | 30-May-2022 |
Record Date | 22-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Election of Chairman of the Meeting | Management | For | For | |||||
2. | Report on the Company’s Activities during the Past Year | Management | For | For | |||||
3. | Approval of Audited Annual Report with Auditor’s Statement and Discharge of the Board of Directors and Management | Management | For | For | |||||
4. | Resolution on Application of Profits or Covering of Losses as per the Adopted Annual Report | Management | For | For | |||||
5a. | Election of Board Member Class II, with a term expiring at the annual general meeting to be held in 2024: Albert Cha | Management | For | For | |||||
5b. | Election of Board Member Class II, with a term expiring at the annual general meeting to be held in 2024: Rafaèle Tordjman | Management | For | For | |||||
5c. | Election of Board Member Class II, with a term expiring at the annual general meeting to be held in 2024: Lars Holtug | Management | For | For | |||||
6. | Election of State-authorized Public Auditor | Management | For | For | |||||
7a. | The Board of Directors proposes to amend the Articles of Association by renewing the authorisation to the Board of Directors to obtain loan against issuance of convertible bonds which gives the right to subscribe up to nominal DKK 9,000,000 new shares in the Company. | Management | For | For | |||||
7b. | The Board of Directors proposes to amend the Articles of Association by adoption of an authorization to the Board of Directors to issue up to nominal 1,000,000 warrants to employees, advisors, consultants and executive management. The exercise price shall be equal to at least the market price at the time of grant. | Management | For | For |
ASTRAZENECA PLC
Security | 046353108 | Meeting Type | Annual |
Ticker Symbol | AZN | Meeting Date | 29-Apr-2022 |
Record Date | 07-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | To receive the Company’s Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2021 | Management | For | For | |||||
2. | To confirm dividends | Management | For | For | |||||
3. | To reappoint PricewaterhouseCoopers LLP as Auditor | Management | For | For | |||||
4. | To authorise the Directors to agree the remuneration of the Auditor | Management | For | For | |||||
5A. | Re-election of Director: Leif Johansson | Management | For | For | |||||
5B. | Re-election of Director: Pascal Soriot | Management | For | For | |||||
5C. | Election of Director: Aradhana Sarin | Management | For | For | |||||
5D. | Re-election of Director: Philip Broadley | Management | For | For | |||||
5E. | Re-election of Director: Euan Ashley | Management | For | For | |||||
5F. | Re-election of Director: Michel Demaré | Management | For | For | |||||
5G. | Re-election of Director: Deborah DiSanzo | Management | For | For | |||||
5H. | Re-election of Director: Diana Layfield | Management | For | For | |||||
5I. | Re-election of Director: Sheri McCoy | Management | For | For | |||||
5J. | Re-election of Director: Tony Mok | Management | For | For | |||||
5K. | Re-election of Director: Nazneen Rahman | Management | For | For | |||||
5L. | Election of Director: Andreas Rummelt | Management | For | For | |||||
5M. | Re-election of Director: Marcus Wallenberg | Management | For | For | |||||
6. | To approve the Annual Report on Remuneration for the year ended 31 December 2021 | Management | For | For | |||||
7. | To authorise limited political donations | Management | For | For | |||||
8. | To authorise the Directors to allot shares | Management | For | For | |||||
9. | To authorise the Directors to disapply pre-emption rights (Special Resolution) | Management | For | For | |||||
10. | To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments (Special Resolution) | Management | For | For | |||||
11. | To authorise the Company to purchase its own shares (Special Resolution) | Management | For | For | |||||
12. | To reduce the notice period for general meetings (Special Resolution) | Management | For | For | |||||
13. | To extend the AstraZenca PLC 2012 Savings Related Share Option Scheme | Management | For | For |
AURINIA PHARMACEUTICALS, INC.
Security | 05156V102 | Meeting Type | Annual |
Ticker Symbol | AUPH | Meeting Date | 17-May-2022 |
Record Date | 14-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1. | Dr. George M. Milne | For | For | |||||||
2. | Mr. Peter Greenleaf | For | For | |||||||
3. | Dr. David R.W. Jayne | For | For | |||||||
4. | Mr. Joseph P. Hagan | For | For | |||||||
5. | Dr. Daniel G. Billen | For | For | |||||||
6. | Mr. R. H. MacKay-Dunn | For | For | |||||||
7. | Ms. Jill Leversage | For | For | |||||||
8. | Mr. Timothy P. Walbert | For | For | |||||||
9. | Dr. Brinda Balakrishnan | For | For | |||||||
2. | Appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm until the close of the 2023 annual general meeting of shareholders or until a successor is appointed. | Management | For | For | ||||||
3. | To approve, on a non-binding advisory basis, a “say on pay” resolution regarding the Company’s executive compensation set forth in the Company’s Proxy Statement/Circular. | Management | For | For |
BEIGENE LTD
Security | 07725L102 | Meeting Type | Annual |
Ticker Symbol | BGNE | Meeting Date | 22-Jun-2022 |
Record Date | 18-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | THAT Anthony C. Hooper be and is hereby re-elected to serve as a Class III director of the Company until the 2025 annual general meeting of the shareholders of the Company and until his successor is duly elected and qualified, subject to his earlier resignation or removal. | Management | For | For | |||||
2. | THAT Ranjeev Krishana be and is hereby re-elected to serve as a Class III director of the Company until the 2025 annual general meeting of the shareholders of the Company and until his successor is duly elected and qualified, subject to his earlier resignation or removal. | Management | For | For | |||||
3. | THAT Xiaodong Wang be and is hereby re-elected to serve as a Class III director of the Company until the 2025 annual general meeting of the shareholders of the Company and until his successor is duly elected and qualified, subject to his earlier resignation or removal. | Management | For | For | |||||
4. | THAT Qingqing Yi be and is hereby re-elected to serve as a Class III director until the 2025 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal. | Management | For | For | |||||
5. | THAT Margaret Dugan be and is hereby re-elected to serve as a Class I director until the 2023 annual general meeting of shareholders and until her successor is duly elected and qualified, subject to her earlier resignation or removal. | Management | For | For | |||||
6. | THAT Alessandro Riva be and is hereby re-elected to serve as a Class I director until the 2023 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal. | Management | For | For | |||||
7. | THAT the selection of Ernst & Young LLP, Ernst & Young Hua Ming LLP and Ernst & Young as the Company’s reporting accounting firms for the fiscal year ending December 31, 2022 be and is hereby approved, ratified and confirmed. | Management | For | For | |||||
8. | THAT the granting of a share issue mandate to the Board of ...(due to space limits, see proxy material for full proposal). | Management | For | For | |||||
9. | THAT the granting of a share repurchase mandate to the Board of ...(due to space limits, see proxy material for full proposal). | Management | For | For | |||||
10. | THAT the Company and its underwriters be and are hereby ...(due to space limits, see proxy material for full proposal). | Management | For | For | |||||
11. | THAT the Company and its underwriters be and are hereby ...(due to space limits, see proxy material for full proposal). | Management | For | For | |||||
12. | THAT the grant of an option to acquire shares to Amgen to allow ...(due to space limits, see proxy material for full proposal). | Management | For | For | |||||
13. | THAT the grant of restricted share units (“RSUs”) with a grant ...(due to space limits, see proxy material for full proposal). | Management | For | For | |||||
14. | THAT the grant of RSUs with a grant date fair value of ...(due to space limits, see proxy material for full proposal). | Management | For | For | |||||
15. | THAT the grant of RSUs with a grant date fair value of ...(due to space limits, see proxy material for full proposal). | Management | For | For | |||||
16. | THAT the Amendment No. 2 to the 2016 Plan to increase the number ...(due to space limits, see proxy material for full proposal). | Management | For | For | |||||
17. | THAT, on a non-binding, advisory basis, the compensation of the ...(due to space limits, see proxy material for full proposal). | Management | For | For | |||||
18. | THAT the adjournment of the Annual Meeting by the chairman, if ...(due to space limits, see proxy material for full proposal). | Management | For | For |
BIOCRYST PHARMACEUTICALS, INC.
Security | 09058V103 | Meeting Type | Annual |
Ticker Symbol | BCRX | Meeting Date | 07-Jun-2022 |
Record Date | 11-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1. | Stephen J. Aselage | For | For | |||||||
2. | Steven K.Galson,M.D,MPH | For | For | |||||||
3. | Kenneth B. Lee, Jr. | For | For | |||||||
4. | Alan G. Levin | For | For | |||||||
2. | To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accountants for 2022. | Management | For | For | ||||||
3. | To approve, on an advisory basis, the Company’s executive compensation. | Management | For | For | ||||||
4. | To approve an amended and restated Stock Incentive Plan, increasing the number of shares available for issuance under the Stock Incentive Plan by 8,000,000 shares. | Management | For | For |
BIOGEN, INC.
Security | 09062X103 | Meeting Type | Annual |
Ticker Symbol | BIIB | Meeting Date | 15-Jun-2022 |
Record Date | 21-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director to serve for a one-year term extending until the 2023 Annual Meeting: Alexander J. Denner | Management | For | For | |||||
1b. | Election of Director to serve for a one-year term extending until the 2023 Annual Meeting: Caroline D. Dorsa | Management | For | For | |||||
1c. | Election of Director to serve for a one-year term extending until the 2023 Annual Meeting: Maria C. Freire | Management | For | For | |||||
1d. | Election of Director to serve for a one-year term extending until the 2023 Annual Meeting: William A. Hawkins | Management | For | For | |||||
1e. | Election of Director to serve for a one-year term extending until the 2023 Annual Meeting: William D. Jones | Management | For | For | |||||
1f. | Election of Director to serve for a one-year term extending until the 2023 Annual Meeting: Jesus B. Mantas | Management | For | For | |||||
1g. | Election of Director to serve for a one-year term extending until the 2023 Annual Meeting: Richard C. Mulligan | Management | For | For | |||||
1h. | Election of Director to serve for a one-year term extending until the 2023 Annual Meeting: Stelios Papadopoulos | Management | For | For | |||||
1i. | Election of Director to serve for a one-year term extending until the 2023 Annual Meeting: Eric K. Rowinsky | Management | For | For | |||||
1j. | Election of Director to serve for a one-year term extending until the 2023 Annual Meeting: Stephen A. Sherwin | Management | For | For | |||||
1k. | Election of Director to serve for a one-year term extending until the 2023 Annual Meeting: Michel Vounatsos | Management | For | For | |||||
2. | To ratify the selection of PricewaterhouseCoopers LLP as Biogen Inc.’s independent registered public accounting firm for the fiscal year ending December 31, 2022. | Management | For | For | |||||
3. | Say on Pay - To approve an advisory vote on executive compensation. | Management | For | For |
BIOHAVEN PHARMACEUTICAL HLDG CO LTD
Security | G11196105 | Meeting Type | Annual |
Ticker Symbol | BHVN | Meeting Date | 28-Apr-2022 |
Record Date | 02-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Director for a term expiring at the 2025 Annual Meeting: John W. Childs | Management | For | For | |||||
1B. | Election of Director for a term expiring at the 2025 Annual Meeting: Gregory H. Bailey | Management | For | For | |||||
1C. | Election of Director for a term expiring at the 2025 Annual Meeting: Kishan Mehta | Management | For | For | |||||
2. | Ratification of appointment of Ernst & Young LLP as independent auditors for fiscal year 2022. | Management | For | For | |||||
3. | To approve, on a non-binding advisory basis, the compensation of the Named Executive Officers. | Management | For | For |
BIOMARIN PHARMACEUTICAL, INC.
Security | 09061G101 | Meeting Type | Annual |
Ticker Symbol | BMRN | Meeting Date | 24-May-2022 |
Record Date | 28-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1. | Mark J. Alles | For | For | |||||||
2. | Elizabeth M. Anderson | For | For | |||||||
3. | Jean-Jacques Bienaimé | For | For | |||||||
4. | Willard Dere | For | For | |||||||
5. | Elaine J. Heron | For | For | |||||||
6. | Maykin Ho | For | For | |||||||
7. | Robert J. Hombach | For | For | |||||||
8. | V. Bryan Lawlis | For | For | |||||||
9. | Richard A. Meier | For | For | |||||||
10. | David E.I. Pyott | For | For | |||||||
11. | Dennis J. Slamon | For | For | |||||||
2. | To ratify the selection of KPMG LLP as the independent registered public accounting firm for BioMarin for the fiscal year ending December 31, 2022. | Management | For | For | ||||||
3. | To approve, on an advisory basis, the compensation of the Company’s Named Executive Officers as disclosed in the Proxy Statement. | Management | For | For |
BIONTECH SE
Security | 09075V102 | Meeting Type | Annual |
Ticker Symbol | BNTX | Meeting Date | 01-Jun-2022 |
Record Date | 27-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
2 | Resolution on appropriation of balance sheet profit | Management | For | For | |||||
3 | Approval of the actions of the Management Board | Management | For | For | |||||
4 | Approval of the actions of the Supervisory Board | Management | For | For | |||||
5 | Appointment of the Auditor for the 2022 Financial Year | Management | For | For | |||||
6 | Resolution on the approval of the remuneration report | Management | For | For | |||||
7 | Resolution on the Amendments to Sec. 9 para. 1 of the Articles of Association (expansion of the Supervisory Board) | Management | For | For | |||||
8.1 | Election to the Supervisory Board: Prof. Dr. Anja Morawietz | Management | For | For | |||||
8.2 | Election to the Supervisory Board: Prof. Dr. Rudolf Staudigl | Management | For | For | |||||
8.3 | Election to the Supervisory Board: Helmut Jeggle | Management | For | For | |||||
9 | Resolution on the remuneration and on the remuneration system for the members of the Supervisory Board and an amendment of Sec. 9 para. 6 of the Articles of Association | Management | For | For | |||||
10a | Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and BioNTech Innovation GmbH as dependent company | Management | For | For | |||||
10b | Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and BioNTech Innovation and Services Marburg GmbH as dependent company | Management | For | For |
BIOTHERYX, INC.
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 24-Sep-2021 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Approval of the amended and restated certificate of incorporation | Management | For | For | |||||
2. | Approval of the 2021 Equity Incentive Plan | Management | For | For |
BIOTHERYX, INC.
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 04-Nov-2021 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Increase to Board Size. | Management | For | For | |||||
2. | Appointment of Director. | Management | For | For |
BLACK DIAMOND THERAPEUTICS, INC.
Security | 09203E105 | Meeting Type | Annual |
Ticker Symbol | BDTX | Meeting Date | 07-Jun-2022 |
Record Date | 13-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1. | Ali Behbahani | For | For | |||||||
2. | Garry E. Menzel | For | For | |||||||
3. | Samarth Kulkarni | For | For | |||||||
2. | To ratify the appointment of PricewaterhouseCoopers LLP as Black Diamond Therapeutics, Inc.’s independent registered accounting firm for the fiscal year ending December 31, 2022. | Management | For | For |
BLUEPRINT MEDICINES CORPORATION
Security | 09627Y109 | Meeting Type | Annual |
Ticker Symbol | BPMC | Meeting Date | 21-Jun-2022 |
Record Date | 25-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1. | Jeffrey W. Albers | For | For | |||||||
2. | Mark Goldberg, M.D. | For | For | |||||||
3. | Nicholas Lydon, Ph.D. | For | For | |||||||
2. | To approve an advisory vote on named executive officer compensation. | Management | For | For | ||||||
3. | Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. | Management | For | For |
BOSTON SCIENTIFIC CORPORATION
Security | 101137107 | Meeting Type | Annual |
Ticker Symbol | BSX | Meeting Date | 05-May-2022 |
Record Date | 11-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Director: Nelda J. Connors | Management | For | For | |||||
1B. | Election of Director: Charles J. Dockendorff | Management | For | For | |||||
1C. | Election of Director: Yoshiaki Fujimori | Management | For | For | |||||
1D. | Election of Director: Donna A. James | Management | For | For | |||||
1E. | Election of Director: Edward J. Ludwig | Management | For | For | |||||
1F. | Election of Director: Michael F. Mahoney | Management | For | For | |||||
1G. | Election of Director: David J. Roux | Management | For | For | |||||
1H. | Election of Director: John E. Sununu | Management | For | For | |||||
1I. | Election of Director: David S. Wichmann | Management | For | For | |||||
1J. | Election of Director: Ellen M. Zane | Management | For | For | |||||
2. | To approve, on a non-binding, advisory basis, named executive officer compensation. | Management | For | For | |||||
3. | To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the 2022 fiscal year. | Management | For | For | |||||
4. | To approve an amendment and restatement of our 2006 Global Employee Stock Ownership Plan (to be renamed as our Employee Stock Purchase Plan), as previously amended and restated, including a request for 10,000,000 additional shares. | Management | For | For |
BRISTOL-MYERS SQUIBB COMPANY
Security | 110122108 | Meeting Type | Annual |
Ticker Symbol | BMY | Meeting Date | 03-May-2022 |
Record Date | 14-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A) | Election of Director: Peter J. Arduini | Management | For | For | |||||
1B) | Election of Director: Giovanni Caforio, M.D. | Management | For | For | |||||
1C) | Election of Director: Julia A. Haller, M.D. | Management | For | For | |||||
1D) | Election of Director: Manuel Hidalgo Medina, M.D., Ph.D. | Management | For | For | |||||
1E) | Election of Director: Paula A. Price | Management | For | For | |||||
1F) | Election of Director: Derica W. Rice | Management | For | For | |||||
1G) | Election of Director: Theodore R. Samuels | Management | For | For | |||||
1H) | Election of Director: Gerald L. Storch | Management | For | For | |||||
1I) | Election of Director: Karen H. Vousden, Ph.D. | Management | For | For | |||||
1J) | Election of Director: Phyllis R. Yale | Management | For | For | |||||
2. | Advisory Vote to Approve the Compensation of our Named Executive Officers. | Management | For | For | |||||
3. | Ratification of the Appointment of an Independent Registered Public Accounting Firm. | Management | For | For | |||||
4. | Shareholder Proposal to Lower the Ownership Threshold for Special Shareholder Meetings to 10%. | Shareholder | Against | For | |||||
5. | Shareholder Proposal on the Adoption of a Board Policy that the Chairperson of the Board be an Independent Director. | Shareholder | For | Against |
CATALENT, INC.
Security | 148806102 | Meeting Type | Annual |
Ticker Symbol | CTLT | Meeting Date | 28-Oct-2021 |
Record Date | 03-Sep-2021 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Director: Madhavan Balachandran | Management | For | For | |||||
1B. | Election of Director: Michael J. Barber | Management | For | For | |||||
1C. | Election of Director: J. Martin Carroll | Management | For | For | |||||
1D. | Election of Director: John Chiminski | Management | For | For | |||||
1E. | Election of Director: Rolf Classon | Management | For | For | |||||
1F. | Election of Director: Rosemary A. Crane | Management | For | For | |||||
1G. | Election of Director: John Greisch | Management | For | For | |||||
1H. | Election of Director: Christa Kreuzburg | Management | For | For | |||||
1I. | Election of Director: Gregory T. Lucier | Management | For | For | |||||
1J. | Election of Director: Donald E. Morel, Jr. | Management | For | For | |||||
1K. | Election of Director: Jack Stahl | Management | For | For | |||||
2. | Ratification of Appointment of Independent Auditor for Fiscal 2022. | Management | For | For | |||||
3. | Advisory Vote to Approve Our Executive Compensation (Say-on-Pay). | Management | For | For | |||||
4. | Advisory Vote on the Frequency of Advisory Votes in Respect of Executive Compensation. | Management | 1 Year | For | |||||
5. | Amend our Certificate of Incorporation to Remove the Limitation on Calling Shareholder Special Meetings. | Management | For | For | |||||
6. | Amend our Certificate of Incorporation to Add a Federal Forum Selection Provision. | Management | For | For | |||||
7. | Amend and Restate our Certificate of Incorporation to (i) Eliminate the Supermajority Vote Requirement for Amendments and (ii) Make Non-Substantive and Conforming Changes. | Management | For | For |
CHARLES RIVER LABORATORIES INTL., INC.
Security | 159864107 | Meeting Type | Annual |
Ticker Symbol | CRL | Meeting Date | 10-May-2022 |
Record Date | 21-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Director: James C. Foster | Management | For | For | |||||
1B. | Election of Director: Nancy C. Andrews | Management | For | For | |||||
1C. | Election of Director: Robert Bertolini | Management | For | For | |||||
1D. | Election of Director: Deborah T. Kochevar | Management | For | For | |||||
1E. | Election of Director: George Llado, Sr. | Management | For | For | |||||
1F. | Election of Director: Martin W. MacKay | Management | For | For | |||||
1G. | Election of Director: George E. Massaro | Management | For | For | |||||
1H. | Election of Director: C. Richard Reese | Management | For | For | |||||
1I. | Election of Director: Richard F. Wallman | Management | For | For | |||||
1J. | Election of Director: Virginia M. Wilson | Management | For | For | |||||
2. | Advisory approval of 2021 Executive Compensation | Management | For | For | |||||
3. | Ratification of PricewaterhouseCoopers LLC as independent registered accounting public firm for 2022 | Management | For | For |
CHEMOCENTRYX, INC.
Security | 16383L106 | Meeting Type | Annual |
Ticker Symbol | CCXI | Meeting Date | 26-May-2022 |
Record Date | 31-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Director: Geoffrey M. Parker | Management | For | For | |||||
1B. | Election of Director: James L. Tyree | Management | For | For | |||||
1C. | Election of Director: David Wheadon, M.D. | Management | For | For | |||||
2. | Ratification of the selection of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2022. | Management | For | For | |||||
3. | Approval, on an advisory basis, of the compensation of the named executive officers as disclosed in the proxy statement pursuant to the compensation disclosure of the Securities and Exchange Commission. | Management | For | For |
CIGNA CORPORATION
Security | 125523100 | Meeting Type | Annual |
Ticker Symbol | CI | Meeting Date | 27-Apr-2022 |
Record Date | 08-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Director: David M. Cordani | Management | For | For | |||||
1B. | Election of Director: William J. DeLaney | Management | For | For | |||||
1C. | Election of Director: Eric J. Foss | Management | For | For | |||||
1D. | Election of Director: Elder Granger, MD, MG, USA (Retired) | Management | For | For | |||||
1E. | Election of Director: Neesha Hathi | Management | For | For | |||||
1F. | Election of Director: George Kurian | Management | For | For | |||||
1G. | Election of Director: Kathleen M. Mazzarella | Management | For | For | |||||
1H. | Election of Director: Mark B. McClellan, MD, PhD | Management | For | For | |||||
1I. | Election of Director: Kimberly A. Ross | Management | For | For | |||||
1J. | Election of Director: Eric C. Wiseman | Management | For | For | |||||
1K. | Election of Director: Donna F. Zarcone | Management | For | For | |||||
2. | Advisory approval of Cigna’s executive compensation. | Management | For | For | |||||
3. | Ratification of the appointment of PricewaterhouseCoopers LLP as Cigna’s independent registered public accounting firm for 2022. | Management | For | For | |||||
4. | Shareholder proposal - Special shareholder meeting improvement. | Shareholder | Against | For | |||||
5. | Shareholder proposal - Gender pay gap report. | Shareholder | Against | For | |||||
6. | Shareholder proposal - Political contributions report. | Shareholder | Against | For |
CURASEN THERAPEUTICS, INC.
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 20-Oct-2021 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Amendment To Certificate of Incorporation. | Management | For | For | |||||
2. | Series A Preferred Stock Extension Financing. | Management | For | For | |||||
3. | Increase to Board Size; Appointment of New Series A Director. | Management | For | For | |||||
4. | Indemnification Agreement. | Management | For | For | |||||
5. | Waiver of Preemptive Rights. | Management | For | For | |||||
6. | General Authority and Ratification. | Management | For | For |
DANAHER CORPORATION
Security | 235851102 | Meeting Type | Annual |
Ticker Symbol | DHR | Meeting Date | 10-May-2022 |
Record Date | 11-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Director to hold office until the 2023 Annual Meeting of Shareholders: Rainer M. Blair | Management | For | For | |||||
1B. | Election of Director to hold office until the 2023 Annual Meeting of Shareholders: Linda Filler | Management | For | For | |||||
1C. | Election of Director to hold office until the 2023 Annual Meeting of Shareholders: Teri List | Management | For | For | |||||
1D. | Election of Director to hold office until the 2023 Annual Meeting of Shareholders: Walter G. Lohr, Jr. | Management | For | For | |||||
1E. | Election of Director to hold office until the 2023 Annual Meeting of Shareholders: Jessica L. Mega, MD, MPH | Management | For | For | |||||
1F. | Election of Director to hold office until the 2023 Annual Meeting of Shareholders: Mitchell P. Rales | Management | For | For | |||||
1G. | Election of Director to hold office until the 2023 Annual Meeting of Shareholders: Steven M. Rales | Management | For | For | |||||
1H. | Election of Director to hold office until the 2023 Annual Meeting of Shareholders: Pardis C. Sabeti, MD, D. PHIL | Management | For | For | |||||
1I. | Election of Director to hold office until the 2023 Annual Meeting of Shareholders: A. Shane Sanders | Management | For | For | |||||
1J. | Election of Director to hold office until the 2023 Annual Meeting of Shareholders: John T. Schwieters | Management | For | For | |||||
1K. | Election of Director to hold office until the 2023 Annual Meeting of Shareholders: Alan G. Spoon | Management | For | For | |||||
1L. | Election of Director to hold office until the 2023 Annual Meeting of Shareholders: Raymond C. Stevens, Ph.D | Management | For | For | |||||
1M. | Election of Director to hold office until the 2023 Annual Meeting of Shareholders: Elias A. Zerhouni, MD | Management | For | For | |||||
2. | To ratify the selection of Ernst & Young LLP as Danaher’s independent registered public accounting firm for the year ending December 31, 2022. | Management | For | For | |||||
3. | To approve on an advisory basis the Company’s named executive officer compensation. | Management | For | For | |||||
4. | To act upon a shareholder proposal requesting that Danaher amend its governing documents to reduce the percentage of shares required for shareholders to call a special meeting of shareholders from 25% to 10%. | Shareholder | Against | For |
DENALI THERAPEUTICS INC.
Security | 24823R105 | Meeting Type | Annual |
Ticker Symbol | DNLI | Meeting Date | 02-Jun-2022 |
Record Date | 11-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1. | Vicki Sato, Ph.D. | For | For | |||||||
2. | Erik Harris | For | For | |||||||
3. | Peter Klein | For | For | |||||||
2. | Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2022. | Management | For | For | ||||||
3. | Advisory vote on executive compensation. | Management | For | For |
DEXCOM, INC.
Security | 252131107 | Meeting Type | Annual |
Ticker Symbol | DXCM | Meeting Date | 19-May-2022 |
Record Date | 31-Mar-2022 |
Item | Proposal | Proposed�� by | Vote | For/Against Management | |||||
1.1 | Election of Class II Director to hold office until our 2023 Annual Meeting: Steven R. Altman | Management | For | For | |||||
1.2 | Election of Class II Director to hold office until our 2023 Annual Meeting: Barbara E. Kahn | Management | For | For | |||||
1.3 | Election of Class II Director to hold office until our 2023 Annual Meeting: Kyle Malady | Management | For | For | |||||
1.4 | Election of Class II Director to hold office until our 2023 Annual Meeting: Jay S. Skyler, MD, MACP | Management | For | For | |||||
2. | To ratify the selection by the Audit Committee of our Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022. | Management | For | For | |||||
3. | To hold a non-binding vote on an advisory resolution to approve executive compensation. | Management | For | For | |||||
4. | To approve the amendment and restatement of our Restated Certificate of Incorporation to (i) effect a 4:1 forward split of our Common Stock (the “Forward Stock Split”) and (ii) increase the number of shares of authorized Common Stock to effectuate the Forward Stock Split. | Management | For | For |
DYNACURE
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 09-Jul-2021 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Approval of the IPO of the Company and waiver of any rights under the Shareholders’ Agreement in connection with the IPO | Management | For | For |
DYNACURE
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 06-Jan-2022 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Share capital increase by contribution in cash, of a nominal amount of 10,528.04 through the issuance of 263,201 new ordinary shares labelled C shares. | Management | For | For | |||||
2. | Cancellation of the preferential subscription right of the shareholders in favor of a named beneficiary. | Management | For | For | |||||
3. | Overall revision of the Company’s by-laws, subject to the condition precedent of the completion of the capital increase covered by the first and second resolutions. | Management | For | For | |||||
4. | Delegation of authority to the Board of Directors to decide to increase the share capital with cancellation of the preferential subscription right, by a maximum nominal amount of 26,506 euros though the issuance of a maximum of 662,650 ABSA C with a nominal value of four euro cents (€0.04) each. | Management | For | For | |||||
5. | Cancellation of the preferential subscription right of the shareholders in favor of a named beneficiary. | Management | For | For | |||||
6. | Delegation of competence to be granted to the Board of Directors to decide the issuance and allocation of a maximum number of 642,789 shares outstanding. | Management | For | For | |||||
7. | Delegation of competence to be granted to the Board of Directors to decide the issuance and allocation of a maximum number of 642,789 BSA2022. | Management | For | For | |||||
8. | Cancellation of the shareholders’ preferential subscription right with respect to the BSA2022 in favor of determined categories of beneficiaries. | Management | For | For | |||||
9. | Delegation of competence granted to the Board of Directors to decide the issuance and allocation of 642,789 AGA2022. | Management | For | For | |||||
10. | Delegation of authority to the Board of Directors to increase the share capital by way of the issue of shares of the Company to participants in a company savings plan (plan d’épargne d’entreprise) established in accordance with articles L. 3332-1 et seq. of the French Labour Code. | Management | For | For | |||||
11. | Power to carry out formalities. | Management | For | For |
DYNACURE
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 23-Jun-2022 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Approval of the annual financial statements for the fiscal year ended December 31, 2021 and discharge of the Chairman of the Board of Directors, the Chief Executive Officer, the Directors and the statutory auditors for the performance of their duties during the past fiscal year. | Management | For | For | |||||
2. | Allocation of the result for the fiscal year ended December 31, 2021. | Management | For | For | |||||
3. | Review of the agreements referred to in Articles L. 225-38 et seq. of the French Commercial Code. | Management | For | For | |||||
4. | Renewal of the terms of office of Bpifrance Investissement, Kurma Partners and Chris Mirabelli as directors. | Management | For | For | |||||
5. | Renewal of the terms of office of Ellen Hukkelhoven as observer. | Management | For | For | |||||
6. | Powers to carry out formalities. | Management | For | For |
EDWARDS LIFESCIENCES CORPORATION
Security | 28176E108 | Meeting Type | Annual |
Ticker Symbol | EW | Meeting Date | 03-May-2022 |
Record Date | 09-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1.1 | Election of Director: Kieran T. Gallahue | Management | For | For | |||||
1.2 | Election of Director: Leslie S. Heisz | Management | For | For | |||||
1.3 | Election of Director: Paul A. LaViolette | Management | For | For | |||||
1.4 | Election of Director: Steven R. Loranger | Management | For | For | |||||
1.5 | Election of Director: Martha H. Marsh | Management | For | For | |||||
1.6 | Election of Director: Michael A. Mussallem | Management | For | For | |||||
1.7 | Election of Director: Ramona Sequeira | Management | For | For | |||||
1.8 | Election of Director: Nicholas J. Valeriani | Management | For | For | |||||
2. | Advisory Vote to Approve Named Executive Officer Compensation | Management | For | For | |||||
3. | Ratification of Appointment of Independent Registered Public Accounting Firm | Management | For | For | |||||
4. | Stockholder Proposal for an Advisory Vote to Reduce the Share Ownership Threshold to Call a Special Meeting | Shareholder | Against | For |
ELI LILLY AND COMPANY
Security | 532457108 | Meeting Type | Annual |
Ticker Symbol | LLY | Meeting Date | 02-May-2022 |
Record Date | 22-Feb-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Director to serve a three-year term: Ralph Alvarez | Management | For | For | |||||
1B. | Election of Director to serve a three-year term: Kimberly H. Johnson | Management | For | For | |||||
1C. | Election of Director to serve a three-year term: Juan R. Luciano | Management | For | For | |||||
2. | Approval, on an advisory basis, of the compensation paid to the company’s named executive officers. | Management | For | For | |||||
3. | Ratification of the appointment of Ernst & Young LLP as the independent auditor for 2022. | Management | For | For | |||||
4. | Approval of amendments to the company’s Articles of Incorporation to eliminate the classified board structure. | Management | For | For | |||||
5. | Approval of amendments to the company’s Articles of Incorporation to eliminate supermajority voting provisions. | Management | For | For | |||||
6. | Approval of amendments to the company’s Articles of Incorporation to give shareholders the ability to amend the company’s bylaws. | Management | For | For | |||||
7. | Shareholder proposal to amend the bylaws to require an independent board chair. | Shareholder | For | Against | |||||
8. | Shareholder proposal to publish an annual report disclosing lobbying activities. | Shareholder | Against | For | |||||
9. | Shareholder proposal to disclose lobbying activities and alignment with public policy positions and statements. | Shareholder | Against | For | |||||
10. | Shareholder proposal to report oversight of risks related to anticompetitive pricing strategies. | Shareholder | Against | For |
ENDEAVOR BIOMEDICINES, INC.
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 03-Mar-2022 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Amendment to Amended and Restated Certificate of Incorporation. | Management | For | For | |||||
2. | Amendment to Series B Preferred Stock Purchase Agreement. | Management | For | For | |||||
3. | General Authority and Ratification. | Management | For | For |
ENDO INTERNATIONAL PLC
Security | G30401106 | Meeting Type | Annual |
Ticker Symbol | ENDP | Meeting Date | 09-Jun-2022 |
Record Date | 11-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director: Mark G. Barberio | Management | For | For | |||||
1b. | Election of Director: Jennifer M. Chao | Management | For | For | |||||
1c. | Election of Director: Blaise Coleman | Management | For | For | |||||
1d. | Election of Director: Shane M. Cooke | Management | For | For | |||||
1e. | Election of Director: Nancy J. Hutson, Ph.D. | Management | For | For | |||||
1f. | Election of Director: Michael Hyatt | Management | For | For | |||||
1g. | Election of Director: William P. Montague | Management | For | For | |||||
1h. | Election of Director: M. Christine Smith, Ph.D. | Management | For | For | |||||
2. | To approve, by advisory vote, named executive officer compensation. | Management | For | For | |||||
3. | To renew the Board’s existing authority to issue shares under Irish law. | Management | For | For | |||||
4. | To renew the Board’s existing authority to opt-out of statutory pre-emption rights under Irish law. | Management | For | For | |||||
5. | To approve the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2022 and to authorize the Board of Directors, acting through the Audit & Finance Committee, to determine the independent registered public accounting firm’s remuneration. | Management | For | For |
FATE THERAPEUTICS, INC.
Security | 31189P102 | Meeting Type | Annual |
Ticker Symbol | FATE | Meeting Date | 09-Jun-2022 |
Record Date | 12-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1. | Timothy P. Coughlin | For | For | |||||||
2. | J. Scott Wolchko | For | For | |||||||
3. | Dr. Shefali Agarwal | For | For | |||||||
2. | To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022. | Management | For | For | ||||||
3. | To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement. | Management | For | For | ||||||
4. | To approve the Fate Therapeutics, Inc. 2022 Stock Option and Incentive Plan. | Management | For | For |
G1 THERAPEUTICS, INC.
Security | 3621LQ109 | Meeting Type | Annual |
Ticker Symbol | GTHX | Meeting Date | 23-Jun-2022 |
Record Date | 25-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1.1 | Election of Class II Director: Alicia Secor | Management | For | For | |||||
2. | An advisory (non-binding) vote to approve executive compensation | Management | For | For | |||||
3. | The ratification of the appointment of PricewaterhouseCoopers LLP as G1 Therapeutics, Inc.’s independent registered public accounting firm for the fiscal year ending December 31, 2022 | Management | For | For |
GALERA THERAPEUTICS, INC.
Security | 36338D108 | Meeting Type | Annual |
Ticker Symbol | GRTX | Meeting Date | 15-Jun-2022 |
Record Date | 22-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1. | Emmett Cunningham | For | For | |||||||
2. | J. Mel Sorensen | For | For | |||||||
2. | To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022. | Management | For | For |
GILEAD SCIENCES, INC.
Security | 375558103 | Meeting Type | Annual |
Ticker Symbol | GILD | Meeting Date | 04-May-2022 |
Record Date | 15-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Director: Jacqueline K. Barton, Ph.D. | Management | For | For | |||||
1B. | Election of Director: Jeffrey A. Bluestone, Ph.D. | Management | For | For | |||||
1C. | Election of Director: Sandra J. Horning, M.D. | Management | For | For | |||||
1D. | Election of Director: Kelly A. Kramer | Management | For | For | |||||
1E. | Election of Director: Kevin E. Lofton | Management | For | For | |||||
1F. | Election of Director: Harish Manwani | Management | For | For | |||||
1G. | Election of Director: Daniel P. O’Day | Management | For | For | |||||
1H. | Election of Director: Javier J. Rodriguez | Management | For | For | |||||
1I. | Election of Director: Anthony Welters | Management | For | For | |||||
2. | To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022. | Management | For | For | |||||
3. | To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement. | Management | For | For | |||||
4. | To approve the Gilead Sciences, Inc. 2022 Equity Incentive Plan. | Management | For | For | |||||
5. | To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board adopt a policy that the Chairperson of the Board of Directors be an independent director. | Shareholder | Against | For | |||||
6. | To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board include one member from Gilead’s non-management employees. | Shareholder | Against | For | |||||
7. | To vote on a stockholder proposal, if properly presented at the meeting, requesting a 10% threshold to call a special stockholder meeting. | Shareholder | Against | For | |||||
8. | To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board publish a third- party review of Gilead’s lobbying activities. | Shareholder | Against | For | |||||
9. | To vote on a stockholder proposal, if properly presented at the meeting, requesting a Board report on oversight of risks related to anticompetitive practices. | Shareholder | Against | For |
GUARDANT HEALTH, INC.
Security | 40131M109 | Meeting Type | Annual |
Ticker Symbol | GH | Meeting Date | 15-Jun-2022 |
Record Date | 18-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Class I Director: Vijaya Gadde | Management | For | For | |||||
1B. | Election of Class I Director: Myrtle Potter | Management | For | For | |||||
2. | Ratification of the appointment of Ernst & Young LLP as Guardant Health, Inc.’s independent registered public accounting firm for the year ending December 31, 2022. | Management | For | For | |||||
3. | Non-binding advisory vote to approve Guardant Health, Inc.’s named executive officer compensation. | Management | For | For |
HCA HEALTHCARE, INC.
Security | 40412C101 | Meeting Type | Annual |
Ticker Symbol | HCA | Meeting Date | 21-Apr-2022 |
Record Date | 25-Feb-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Director: Thomas F. Frist III | Management | For | For | |||||
1B. | Election of Director: Samuel N. Hazen | Management | For | For | |||||
1C. | Election of Director: Meg G. Crofton | Management | For | For | |||||
1D. | Election of Director: Robert J. Dennis | Management | For | For | |||||
1E. | Election of Director: Nancy-Ann DeParle | Management | For | For | |||||
1F. | Election of Director: William R. Frist | Management | For | For | |||||
1G. | Election of Director: Charles O. Holliday, Jr. | Management | For | For | |||||
1H. | Election of Director: Hugh F. Johnston | Management | For | For | |||||
1I. | Election of Director: Michael W. Michelson | Management | For | For | |||||
1J. | Election of Director: Wayne J. Riley, M.D. | Management | For | For | |||||
1K. | Election of Director: Andrea B. Smith | Management | For | For | |||||
2. | To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2022. | Management | For | For | |||||
3. | Advisory vote to approve named executive officer compensation. | Management | For | For | |||||
4. | Stockholder proposal, if properly presented at the meeting, regarding political spending disclosure. | Shareholder | Against | For | |||||
5. | Stockholder proposal, if properly presented at the meeting, regarding lobbying disclosure. | Shareholder | Against | For |
HEALTHEQUITY, INC.
Security | 42226A107 | Meeting Type | Annual |
Ticker Symbol | HQY | Meeting Date | 23-Jun-2022 |
Record Date | 29-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Robert Selander | Management | For | For | |||||
1b. | Jon Kessler | Management | For | For | |||||
1c. | Stephen Neeleman, M.D. | Management | For | For | |||||
1d. | Frank Corvino | Management | For | For | |||||
1e. | Adrian Dillon | Management | For | For | |||||
1f. | Evelyn Dilsaver | Management | For | For | |||||
1g. | Debra McCowan | Management | For | For | |||||
1h. | Rajesh Natarajan | Management | For | For | |||||
1i. | Stuart Parker | Management | For | For | |||||
1j. | Ian Sacks | Management | For | For | |||||
1k. | Gayle Wellborn | Management | For | For | |||||
2. | To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending January 31, 2023. | Management | For | For | |||||
3. | To approve, on a non-binding, advisory basis, the fiscal 2022 compensation paid to our named executive officers. | Management | For | For |
HELIX ACQUISITION CORP
Security | G4444C102 | Meeting Type | Special |
Ticker Symbol | HLXA | Meeting Date | 31-Mar-2022 |
Record Date | 07-Jan-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | A proposal, as an ordinary resolution, to approve the business combination agreement, dated as of October 4, 2021, by and among Helix, MoonLake Immunotherapeutics AG, a Swiss stock corporation (“MoonLake”), certain securityholders of MoonLake (the “ML Parties”),and the other parties thereto,a copy of which is attached to the accompanying proxy statement as Annex A-1, and approve the transactions contemplated by the Business Combination Agreement (the “Business Combination”) and other ...(due to space limits, see proxy material for full proposal). | Management | For | For | |||||
2A. | Binding Organizational Documents Proposal A: a proposal, as an ordinary resolution, to approve the change in authorized share capital of Helix, from US$55,500 divided into 500,000,000 Class A Ordinary Shares, 50,000,000 Class B Ordinary Shares, and 5,000,000 preference shares, to US$65,500 divided into 500,000,000 Class A Ordinary Shares, 50,000,000 Class B Ordinary Shares,100,000,000 Class C Ordinary Shares, and 5,000,000 preference shares by the creation of an additional 100,000,000 ...(due to space limits, see proxy material for full proposal). | Management | For | For | |||||
2B. | Binding Organizational Documents Proposal B: a proposal, as a special resolution, to approve the change in Helix’s name, from “Helix Acquisition Corp.” to “MoonLake Immunotherapeutics”. | Management | For | For | |||||
2C. | Binding Organizational Documents Proposal C: a proposal, as special resolution, to approve the adoption of the second amended and restated memorandum and articles of association of the Company (the “Proposed MAA”), a copy of which is attached to the accompanying proxy statement as Annex B. | Management | For | For | |||||
3A. | Advisory Organizational Documents Proposal A: assuming Binding Organizational Documents Proposal A is approved, a proposal to approve an amendment to the Existing MAA to provide for an increase in the authorized share capital from US$55,500 divided into 500,000,000 Class A Ordinary Shares of a par value of US$0.0001 each, 50,000,000 Class B Ordinary Shares of a par value of US$0.0001 each and 5,000,000 preference shares of a par value of US$0.0001 each to US$65,500 divided into 500,000,000 ...(due to space limits, see proxy material for full proposal). | Management | For | For | |||||
3B. | Advisory Organizational Documents Proposal B: assuming Binding Organizational Documents Proposal A is approved, a proposal to approve an amendment to the Existing MAA to provide (i) for the rights attaching to Class A Ordinary Shares and Class C Ordinary Shares, (ii) that Class C Ordinary Shares may be transferred only as set out in the amended and restated shareholders’ agreement to be entered by Helix, MoonLake and each ML Party at the Closing (the “A&R Shareholders’ Agreement”)to be in effect ...(due to space limits, see proxy material for full proposal). | Management | For | For | |||||
3C. | Advisory Organizational Documents Proposal C: a proposal to require the consent of a class of shares, voting separately, for any variation of the rights of such class instead of the board of directors’ ability to vary class rights without consent from shareholders of a class where the board of directors considered the variation would not have a material adverse effect on such rights. | Management | For | For | |||||
3D. | Advisory Organizational Documents Proposal D: a proposal to remove the ability of the board of directors to remove one of their members for cause. | Management | For | For | |||||
3E. | Advisory Organizational Documents Proposal E: a proposal for an extended notice period for shareholders to nominate a director without a timely public announcement. | Management | For | For | |||||
3F. | Advisory Organizational Documents Proposal F: a proposal for restrictions on the ability of non-employee directors to pursue certain business opportunities wherein the Company retains its interest in any opportunity offered to any non-employee director if such opportunity is expressly offered to such non-employee director solely in his or her capacity as a director. | Management | For | For | |||||
3G. | Advisory Organizational Documents Proposal G: a proposal for the elimination of the minimum shareholder requirement in general meeting proposals and director nomination provisions. | Management | For | For | |||||
3H. | Advisory Organizational Documents Proposal H: a proposal for certain additional changes, including, among other things (i) removing terms providing for the automatic conversion of Class B Ordinary Shares to Class A Ordinary Shares in connection with consummation of an initial business combination; (ii) removing shareholder redemption provisions; (iii) removing the limitation on paying cash remuneration to directors prior to the consummation of an initial business combination iv) removing the ...(due to space limits, see proxy material for full proposal). | Management | For | For | |||||
4. | A proposal, as an ordinary resolution, to approve, for the purpose of complying with the applicable Nasdaq listing rules, (i) the issuance of Class A Ordinary Shares to certain of the ML Parties (the “BVF Shareholders”) and Class C Ordinary Shares to the ML Parties (other than the BVF Shareholders), including the Class A Ordinary Shares issuable upon the exchange of MoonLake Common Shares and simultaneous surrender of Class C Ordinary Sharesby such ML Parties, pursuant to the terms of the Business ...(due to space limits, see proxy material for full proposal). | Management | For | For | |||||
5. | A proposal, as an ordinary resolution, to approve the MoonLake Immunotherapeutics 2022 Equity Incentive Plan, a copy of which is attached to the accompanying proxy statement as Annex C (we refer to this proposal as the “Incentive Plan Proposal”) | Management | For | For | |||||
6. | A proposal, as an ordinary resolution, to approve the adjournment of the extraordinary general meeting to a later date or dates, (A) to the extent necessary to ensure that any required supplement or amendment to the proxy statement is provided to Helix’s shareholders; (B) if, as of the time for which the extraordinary general meeting is originally scheduled, there are insufficient ordinary shares represented (either in person or by proxy) to constitute a quorum necessary to ...(due to space limits, see proxy material for full proposal). | Management | For | For |
HOLOGIC, INC.
Security | 436440101 | Meeting Type | Annual |
Ticker Symbol | HOLX | Meeting Date | 10-Mar-2022 |
Record Date | 11-Jan-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Director: Stephen P. MacMillan | Management | For | For | |||||
1B. | Election of Director: Sally W. Crawford | Management | For | For | |||||
1C. | Election of Director: Charles J. Dockendorff | Management | For | For | |||||
1D. | Election of Director: Scott T. Garrett | Management | For | For | |||||
1E. | Election of Director: Ludwig N. Hantson | Management | For | For | |||||
1F. | Election of Director: Namal Nawana | Management | For | For | |||||
1G. | Election of Director: Christiana Stamoulis | Management | For | For | |||||
1H. | Election of Director: Amy M. Wendell | Management | For | For | |||||
2. | A non-binding advisory resolution to approve executive compensation. | Management | For | For | |||||
3. | Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for fiscal 2022. | Management | For | For |
HORIZON THERAPEUTICS PLC
Security | G46188101 | Meeting Type | Annual |
Ticker Symbol | HZNP | Meeting Date | 28-Apr-2022 |
Record Date | 24-Feb-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Class II Director: Michael Grey | Management | For | For | |||||
1B. | Election of Class II Director: Jeff Himawan, Ph.D. | Management | For | For | |||||
1C. | Election of Class II Director: Susan Mahony, Ph.D. | Management | For | For | |||||
2. | Approval of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2022 and authorization of the Audit Committee to determine the auditors’ remuneration. | Management | For | For | |||||
3. | Approval, on an advisory basis, of the compensation of our named executive officers, as disclosed in the Proxy Statement. | Management | For | For | |||||
4. | Authorization for us and/or any of our subsidiaries to make market purchases or overseas market purchases of our ordinary shares. | Management | For | For | |||||
5. | Approval of the Amended and Restated 2020 Equity Incentive Plan. | Management | For | For |
HOTSPOT THERAPEUTICS, INC.
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 16-Nov-2021 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Fourth Amended and Restated Certificate of Incorporation | Management | For | For | |||||
2. | Amendment to 2017 Stock Option and Grant Plan | Management | For | For | |||||
3. | General Resolutions | Management | For | For |
HOTSPOT THERAPEUTICS, INC.
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 16-Nov-2021 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Waiver of Right of First Offer. | Management | For | For |
HUMANA INC.
Security | 444859102 | Meeting Type | Annual |
Ticker Symbol | HUM | Meeting Date | 21-Apr-2022 |
Record Date | 28-Feb-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A) | Election of Director: Raquel C. Bono, M.D. | Management | For | For | |||||
1B) | Election of Director: Bruce D. Broussard | Management | For | For | |||||
1C) | Election of Director: Frank A. D’Amelio | Management | For | For | |||||
1D) | Election of Director: David T. Feinberg, M.D. | Management | For | For | |||||
1E) | Election of Director: Wayne A. I. Frederick, M.D. | Management | For | For | |||||
1F) | Election of Director: John W. Garratt | Management | For | For | |||||
1G) | Election of Director: Kurt J. Hilzinger | Management | For | For | |||||
1H) | Election of Director: David A. Jones, Jr. | Management | For | For | |||||
1I) | Election of Director: Karen W. Katz | Management | For | For | |||||
1J) | Election of Director: Marcy S. Klevorn | Management | For | For | |||||
1K) | Election of Director: William J. McDonald | Management | For | For | |||||
1L) | Election of Director: Jorge S. Mesquita | Management | For | For | |||||
1M) | Election of Director: James J. O’Brien | Management | For | For | |||||
2) | The ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm. | Management | For | For | |||||
3) | Non-binding advisory vote for the approval of the compensation of the named executive officers as disclosed in the 2022 proxy statement. | Management | For | For |
ICON PLC
Security | G4705A100 | Meeting Type | Annual |
Ticker Symbol | ICLR | Meeting Date | 20-Jul-2021 |
Record Date | 10-Jun-2021 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1.1 | Election of Director: Mr. Ciaran Murray | Management | For | For | |||||
1.2 | Election of Director: Ms. Joan Garahy | Management | For | For | |||||
1.3 | Election of Director: Mr. Eugene McCague | Management | For | For | |||||
2.1 | Subject to and conditional upon the completion of the Acquisition to elect: Mr. Colin Shannon | Management | For | For | |||||
2.2 | Subject to and conditional upon the completion of the Acquisition to elect: Dr. Linda Grais | Management | For | For | |||||
3. | To review the Company’s affairs and consider the Accounts and Reports. | Management | For | For | |||||
4. | To authorise the fixing of the Auditors’ Remuneration. | Management | For | For | |||||
5. | To authorise the Company to allot shares. | Management | For | For | |||||
6. | To disapply the statutory pre-emption rights. | Management | For | For | |||||
7. | To disapply the statutory pre-emption rights for funding capital investment or acquisitions. | Management | For | For | |||||
8. | To authorise the Company to make market purchases of shares. | Management | For | For | |||||
9. | To authorise the price range at which the Company can reissue shares that it holds as treasury shares. | Management | For | For |
IDEXX LABORATORIES, INC.
Security | 45168D104 | Meeting Type | Annual |
Ticker Symbol | IDXX | Meeting Date | 11-May-2022 |
Record Date | 14-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Director (Proposal One): Jonathan W. Ayers | Management | For | For | |||||
1B. | Election of Director (Proposal One): Stuart M. Essig, PhD | Management | For | For | |||||
1C. | Election of Director (Proposal One): Jonathan J. Mazelsky | Management | For | For | |||||
1D. | Election of Director (Proposal One): M. Anne Szostak | Management | For | For | |||||
2. | Ratification of Appointment of Independent Registered Public Accounting Firm. To ratify the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the current fiscal year (Proposal Two). | Management | For | For | |||||
3. | Advisory Vote on Executive Compensation. To approve a nonbinding advisory resolution on the Company’s executive compensation (Proposal Three). | Management | For | For |
ILLUMINA, INC.
Security | 452327109 | Meeting Type | Annual |
Ticker Symbol | ILMN | Meeting Date | 26-May-2022 |
Record Date | 31-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Director: Frances Arnold, Ph.D. | Management | For | For | |||||
1B. | Election of Director: Francis A. deSouza | Management | For | For | |||||
1C. | Election of Director: Caroline D. Dorsa | Management | For | For | |||||
1D. | Election of Director: Robert S. Epstein, M.D. | Management | For | For | |||||
1E. | Election of Director: Scott Gottlieb, M.D. | Management | For | For | |||||
1F. | Election of Director: Gary S. Guthart, Ph.D. | Management | For | For | |||||
1G. | Election of Director: Philip W. Schiller | Management | For | For | |||||
1H. | Election of Director: Susan E. Siegel | Management | For | For | |||||
1I. | Election of Director: John W. Thompson | Management | For | For | |||||
2. | To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending January 1, 2023. | Management | For | For | |||||
3. | To approve, on an advisory basis, the compensation of the named executive officers as disclosed in the Proxy Statement. | Management | For | For | |||||
4. | To approve, on an advisory basis, a stockholder proposal regarding the right of stockholders to call special meetings. | Shareholder | Against | For | |||||
5. | To approve an amendment to our Amended and Restated Certificate of Incorporation to permit stockholders to call special meetings. | Management | For | For |
INTELLIA THERAPEUTICS, INC.
Security | 45826J105 | Meeting Type | Annual |
Ticker Symbol | NTLA | Meeting Date | 14-Jun-2022 |
Record Date | 18-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1 | Caroline Dorsa | For | For | |||||||
2 | G. Keresty, PhD M.P.H. | For | For | |||||||
3 | John M. Leonard, M.D. | For | For | |||||||
2. | Ratification of the appointment of Deloitte & Touche LLP as Intellia’s independent registered public accounting firm for the fiscal year ending December 31, 2022. | Management | For | For | ||||||
3. | Approve, on a non-binding advisory basis, the compensation of the named executive officers. | Management | For | For |
INTERCEPT PHARMACEUTICALS, INC.
Security | 45845P108 | Meeting Type | Annual |
Ticker Symbol | ICPT | Meeting Date | 25-May-2022 |
Record Date | 06-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director to serve until the 2023 Annual Meeting: Paolo Fundarò | Management | For | For | |||||
1b. | Election of Director to serve until the 2023 Annual Meeting: Jerome Durso | Management | For | For | |||||
1c. | Election of Director to serve until the 2023 Annual Meeting: Srinivas Akkaraju, M.D., Ph.D. | Management | For | For | |||||
1d. | Election of Director to serve until the 2023 Annual Meeting: Luca Benatti, Ph.D. | Management | For | For | |||||
1e. | Election of Director to serve until the 2023 Annual Meeting: Daniel Bradbury | Management | For | For | |||||
1f. | Election of Director to serve until the 2023 Annual Meeting: Keith Gottesdiener, M.D. | Management | For | For | |||||
1g. | Election of Director to serve until the 2023 Annual Meeting: Nancy Miller-Rich | Management | For | For | |||||
1h. | Election of Director to serve until the 2023 Annual Meeting: Mark Pruzanski, M.D. | Management | For | For | |||||
1i. | Election of Director to serve until the 2023 Annual Meeting: Dagmar Rosa-Bjorkeson | Management | For | For | |||||
1j. | Election of Director to serve until the 2023 Annual Meeting: Gino Santini | Management | For | For | |||||
1k. | Election of Director to serve until the 2023 Annual Meeting: Glenn Sblendorio | Management | For | For | |||||
2. | FOR the approval of the Company’s Amended and Restated Equity Incentive Plan. | Management | For | For | |||||
3. | FOR the approval, on a non-binding, advisory basis, of the compensation of the Company’s named executive officers. | Management | For | For | |||||
4. | FOR the ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2022. | Management | For | For |
INTRA-CELLULAR THERAPIES, INC.
Security | 46116X101 | Meeting Type | Annual |
Ticker Symbol | ITCI | Meeting Date | 09-Jun-2022 |
Record Date | 19-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1.1 | Election of Director to serve a three-year term expiring in 2025: Sharon Mates, Ph.D. | Management | For | For | |||||
1.2 | Election of Director to serve a three-year term expiring in 2025: Rory B. Riggs | Management | For | For | |||||
1.3 | Election of Director to serve a three-year term expiring in 2025: Robert L. Van Nostrand | Management | For | For | |||||
2. | To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2022. | Management | For | For | |||||
3. | To approve by an advisory vote the compensation of the Company’s named executive officers, as disclosed in the proxy statement. | Management | For | For | |||||
4. | To approve by an advisory vote the frequency of holding an advisory vote on the compensation of the Company’s named executive officers. | Management | 1 Year | For |
INTUITIVE SURGICAL, INC.
Security | 46120E602 | Meeting Type | Special |
Ticker Symbol | ISRG | Meeting Date | 20-Sep-2021 |
Record Date | 18-Aug-2021 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | TO APPROVE THE COMPANY’S AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK FOR THE PURPOSE OF EFFECTING A THREE-FOR-ONE STOCK SPLIT. | Management | For | For |
INTUITIVE SURGICAL, INC.
Security | 46120E602 | Meeting Type | Annual |
Ticker Symbol | ISRG | Meeting Date | 28-Apr-2022 |
Record Date | 01-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Director: Craig H. Barratt, Ph.D. | Management | For | For | |||||
1B. | Election of Director: Joseph C. Beery | Management | For | For | |||||
1C. | Election of Director: Gary S. Guthart, Ph.D. | Management | For | For | |||||
1D. | Election of Director: Amal M. Johnson | Management | For | For | |||||
1E. | Election of Director: Don R. Kania, Ph.D. | Management | For | For | |||||
1F. | Election of Director: Amy L. Ladd, M.D. | Management | For | For | |||||
1G. | Election of Director: Keith R. Leonard, Jr. | Management | For | For | |||||
1H. | Election of Director: Alan J. Levy, Ph.D. | Management | For | For | |||||
1I. | Election of Director: Jami Dover Nachtsheim | Management | For | For | |||||
1J. | Election of Director: Monica P. Reed, M.D. | Management | For | For | |||||
1K. | Election of Director: Mark J. Rubash | Management | For | For | |||||
2. | To approve, by advisory vote, the compensation of the Company’s Named Executive Officers. | Management | For | For | |||||
3. | The ratification of appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. | Management | For | For | |||||
4. | To approve the Company’s Amended and Restated 2010 Incentive Award Plan. | Management | For | For |
INVETX, INC.
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 29-Mar-2021 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Election of Director | Management | For | For |
INVETX, INC.
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 29-Mar-2021 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Amended and Restated Certificate of Incorporation | Management | For | For | |||||
2. | Amended and Restated 2020 Equity Incentive Plan | Management | For | For | |||||
3. | Amendment to Bylaws | Management | For | For | |||||
4. | Sale and Issuance of Series B Preferred Stock | Management | For | For | |||||
5. | Protective Provision Consent | Management | For | For | |||||
6. | Waiver of Participation Rights | Management | For | For | |||||
7. | Ratification of Series B Financing | Management | For | For |
IONIS PHARMACEUTICALS, INC.
Security | 462222100 | Meeting Type | Annual |
Ticker Symbol | IONS | Meeting Date | 02-Jun-2022 |
Record Date | 05-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1. | Allene M. Diaz | For | For | |||||||
2. | Michael Hayden | For | For | |||||||
3. | Joseph Klein, III | For | For | |||||||
4. | Joseph Loscalzo | For | For | |||||||
2. | To approve, by non-binding vote, executive compensation. | Management | For | For | ||||||
3. | Ratify the Audit Committee’s selection of Ernst & Young LLP as independent auditors for the 2022 fiscal year. | Management | For | For |
IQVIA HOLDINGS, INC.
Security | 46266C105 | Meeting Type | Annual |
Ticker Symbol | IQV | Meeting Date | 12-Apr-2022 |
Record Date | 15-Feb-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1. | John P. Connaughton | For | For | |||||||
2. | John G. Danhakl | For | For | |||||||
3. | James A. Fasano | For | For | |||||||
4. | Leslie Wims Morris | For | For | |||||||
2. | Amendment to Certificate of Incorporation to declassify the Board of Directors over time and provide for the annual election of all directors. | Management | For | For | ||||||
3. | Advisory (non-binding) vote to approve executive compensation (say-on-pay). | Management | For | For | ||||||
4. | If properly presented, a shareholder proposal regarding majority voting in uncontested director elections. | Management | Against | For | ||||||
5. | The ratification of the appointment of PricewaterhouseCoopers LLP as IQVIA Holdings Inc.’s independent registered public accounting firm for the year ending December 31, 2022. | Management | For | For |
JAZZ PHARMACEUTICALS PLC
Security | G50871105 | Meeting Type | Special |
Ticker Symbol | JAZZ | Meeting Date | 23-Sep-2021 |
Record Date | 19-Aug-2021 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | To grant the board of directors authority under Irish law to allot and issue ordinary shares for cash without first offering those ordinary shares to existing shareholders pursuant to the statutory pre-emption right that would otherwise apply. | Management | For | For | |||||
2. | To approve any motion to adjourn the extraordinary general meeting, or any adjournments thereof, to another time and place to solicit additional proxies if there are insufficient votes at the time of the extraordinary general meeting to approve Proposal 1. | Management | For | For |
JOHNSON & JOHNSON
Security | 478160104 | Meeting Type | Annual |
Ticker Symbol | JNJ | Meeting Date | 28-Apr-2022 |
Record Date | 01-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Director: Darius Adamczyk | Management | For | For | |||||
1B. | Election of Director: Mary C. Beckerle | Management | For | For | |||||
1C. | Election of Director: D. Scott Davis | Management | For | For | |||||
1D. | Election of Director: Ian E. L. Davis | Management | For | For | |||||
1E. | Election of Director: Jennifer A. Doudna | Management | For | For | |||||
1F. | Election of Director: Joaquin Duato | Management | For | For | |||||
1G. | Election of Director: Alex Gorsky | Management | For | For | |||||
1H. | Election of Director: Marillyn A. Hewson | Management | For | For | |||||
1I. | Election of Director: Hubert Joly | Management | For | For | |||||
1J. | Election of Director: Mark B. McClellan | Management | For | For | |||||
1K. | Election of Director: Anne M. Mulcahy | Management | For | For | |||||
1L. | Election of Director: A. Eugene Washington | Management | For | For | |||||
1M. | Election of Director: Mark A. Weinberger | Management | For | For | |||||
1N. | Election of Director: Nadja Y. West | Management | For | For | |||||
2. | Advisory Vote to Approve Named Executive Officer Compensation. | Management | For | For | |||||
3. | Approval of the Company’s 2022 Long-Term Incentive Plan. | Management | For | For | |||||
4. | Ratification of Appointment of PricewaterhouseCoopers LLP as the Independent Registered Public Accounting Firm for 2022. | Management | For | For | |||||
5. | Proposal Withdrawn (Federal Securities Laws Mandatory Arbitration Bylaw). | Shareholder | Against | ||||||
6. | Civil Rights, Equity, Diversity & Inclusion Audit Proposal. | Shareholder | Against | For | |||||
7. | Third Party Racial Justice Audit. | Shareholder | Against | For | |||||
8. | Report on Government Financial Support and Access to COVID-19 Vaccines and Therapeutics. | Shareholder | Against | For | |||||
9. | Report on Public Health Costs of Protecting Vaccine Technology. | Shareholder | Against | For | |||||
10. | Discontinue Global Sales of Baby Powder Containing Talc. | Shareholder | Against | For | |||||
11. | Request for Charitable Donations Disclosure. | Shareholder | Against | For | |||||
12. | Third Party Review and Report on Lobbying Activities Alignment with Position on Universal Health Coverage. | Shareholder | Against | For | |||||
13. | Adopt Policy to Include Legal and Compliance Costs in Incentive Compensation Metrics. | Shareholder | Against | For | |||||
14. | CEO Compensation to Weigh Workforce Pay and Ownership. | Shareholder | Against | For |
KALVISTA PHARMACEUTICALS, INC.
Security | 483497103 | Meeting Type | Annual |
Ticker Symbol | KALV | Meeting Date | 30-Sep-2021 |
Record Date | 10-Aug-2021 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Class III Director until the 2024 annual meeting: ALBERT CHA | Management | For | For | |||||
1B. | Election of Class III Director until the 2024 annual meeting: MARTIN EDWARDS | Management | For | For | |||||
1C. | Election of Class III Director until the 2024 annual meeting: NANCY STUART | Management | For | For | |||||
2. | The ratification of the selection, by the audit committee of our board, of Deloitte & Touche LLP as our independent registered public accounting firm for the year ending April 30, 2022. | Management | For | For | |||||
3. | Approval, on a non-binding advisory basis, of the compensation paid by us to our named executive officers as disclosed in the Proxy Statement. | Management | For | For |
KARUNA THERAPEUTICS, INC.
Security | 48576A100 | Meeting Type | Annual |
Ticker Symbol | KRTX | Meeting Date | 15-Jun-2022 |
Record Date | 18-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Class III Director: Steven Paul, M.D. | Management | For | For | |||||
1b. | Election of Class III Director: Atul Pande, M.D. | Management | For | For | |||||
1c. | Election of Class III Director: Denice Torres | Management | For | For | |||||
2. | To approve, on an advisory, non-binding basis, the compensation paid to our named executive officers. | Management | For | For | |||||
3. | To approve, on an advisory, non-binding basis, the frequency of future votes on the compensation of our named executive officers. | Management | 1 Year | For | |||||
4. | To ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. | Management | For | For |
LABORATORY CORP. OF AMERICA HOLDINGS
Security | 50540R409 | Meeting Type | Annual |
Ticker Symbol | LH | Meeting Date | 11-May-2022 |
Record Date | 16-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Director: Kerrii B. Anderson | Management | For | For | |||||
1B. | Election of Director: Jean-Luc Bélingard | Management | For | For | |||||
1C. | Election of Director: Jeffrey A. Davis | Management | For | For | |||||
1D. | Election of Director: D. Gary Gilliland, M.D., Ph.D. | Management | For | For | |||||
1E. | Election of Director: Garheng Kong, M.D., Ph.D. | Management | For | For | |||||
1F. | Election of Director: Peter M. Neupert | Management | For | For | |||||
1G. | Election of Director: Richelle P. Parham | Management | For | For | |||||
1H. | Election of Director: Adam H. Schechter | Management | For | For | |||||
1I. | Election of Director: Kathryn E. Wengel | Management | For | For | |||||
1J. | Election of Director: R. Sanders Williams, M.D. | Management | For | For | |||||
2. | To approve, by non-binding vote, executive compensation. | Management | For | For | |||||
3. | Ratification of the appointment of Deloitte and Touche LLP as Laboratory Corporation of America Holdings’ independent registered public accounting firm for the year ending December 31, 2022. | Management | For | For | |||||
4. | Shareholder proposal seeking an amendment to our governing documents relating to procedural requirements in connection with shareholders’ rights to call a special meeting. | Shareholder | Against | For |
MCKESSON CORPORATION
Security | 58155Q103 | Meeting Type | Annual |
Ticker Symbol | MCK | Meeting Date | 23-Jul-2021 |
Record Date | 28-May-2021 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Director for a one-year term: Dominic J. Caruso | Management | For | For | |||||
1B. | Election of Director for a one-year term: Donald R. Knauss | Management | For | For | |||||
1C. | Election of Director for a one-year term: Bradley E. Lerman | Management | For | For | |||||
1D. | Election of Director for a one-year term: Linda P. Mantia | Management | For | For | |||||
1E. | Election of Director for a one-year term: Maria Martinez | Management | For | For | |||||
1F. | Election of Director for a one-year term: Edward A. Mueller | Management | For | For | |||||
1G. | Election of Director for a one-year term: Susan R. Salka | Management | For | For | |||||
1H. | Election of Director for a one-year term: Brian S. Tyler | Management | For | For | |||||
1I. | Election of Director for a one-year term: Kenneth E. Washington | Management | For | For | |||||
2. | Ratification of the appointment of Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending March 31, 2022. | Management | For | For | |||||
3. | Advisory vote on executive compensation. | Management | For | For | |||||
4. | Shareholder proposal on action by written consent of shareholders. | Shareholder | Against | For |
MEDPACE HOLDINGS, INC.
Security | 58506Q109 | Meeting Type | Annual |
Ticker Symbol | MEDP | Meeting Date | 20-May-2022 |
Record Date | 24-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1. | August J. Troendle | For | For | |||||||
2. | Ashley M. Keating | For | For | |||||||
2. | To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022. | Management | For | For | ||||||
3. | To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy statement for the 2022 Annual Meeting. | Management | For | For |
MEDTRONIC PLC
Security | G5960L103 | Meeting Type | Annual |
Ticker Symbol | MDT | Meeting Date | 09-Dec-2021 |
Record Date | 14-Oct-2021 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Director until the 2022 Annual General Meeting: Richard H. Anderson | Management | For | For | |||||
1B. | Election of Director until the 2022 Annual General Meeting: Craig Arnold | Management | For | For | |||||
1C. | Election of Director until the 2022 Annual General Meeting: Scott C. Donnelly | Management | For | For | |||||
1D. | Election of Director until the 2022 Annual General Meeting: Andrea J. Goldsmith, Ph.D. | Management | For | For | |||||
1E. | Election of Director until the 2022 Annual General Meeting: Randall J. Hogan, III | Management | For | For | |||||
1F. | Election of Director until the 2022 Annual General Meeting: Kevin E. Lofton | Management | For | For | |||||
1G. | Election of Director until the 2022 Annual General Meeting: Geoffrey S. Martha | Management | For | For | |||||
1H. | Election of Director until the 2022 Annual General Meeting: Elizabeth G. Nabel, M.D. | Management | For | For | |||||
1I. | Election of Director until the 2022 Annual General Meeting: Denise M. O’Leary | Management | For | For | |||||
1J. | Election of Director until the 2022 Annual General Meeting: Kendall J. Powell | Management | For | For | |||||
2. | Ratifying, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the Company’s independent auditor for fiscal year 2022 and authorizing, in a binding vote, the Board of Directors, acting through the Audit Committee, to set the auditor’s remuneration. | Management | For | For | |||||
3. | Approving, on an advisory basis, the Company’s executive compensation. | Management | For | For | |||||
4. | Approving, on an advisory basis, the frequency of Say- on-Pay votes. | Management | 1 Year | For | |||||
5. | Approving the new 2021 Medtronic plc Long Term Incentive Plan. | Management | For | For | |||||
6. | Renewing the Board of Directors’ authority to issue shares under Irish law. | Management | For | For | |||||
7. | Renewing the Board of Directors’ authority to opt out of pre- emption rights under Irish law. | Management | For | For | |||||
8. | Authorizing the Company and any subsidiary of the Company to make overseas market purchases of Medtronic ordinary shares. | Management | For | For |
MERCK & CO., INC.
Security | 58933Y105 | Meeting Type | Annual |
Ticker Symbol | MRK | Meeting Date | 24-May-2022 |
Record Date | 25-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Director: Douglas M. Baker, Jr. | Management | For | For | |||||
1B. | Election of Director: Mary Ellen Coe | Management | For | For | |||||
1C. | Election of Director: Pamela J. Craig | Management | For | For | |||||
1D. | Election of Director: Robert M. Davis | Management | For | For | |||||
1E. | Election of Director: Kenneth C. Frazier | Management | For | For | |||||
1F. | Election of Director: Thomas H. Glocer | Management | For | For | |||||
1G. | Election of Director: Risa J. Lavizzo-Mourey, M.D. | Management | For | For | |||||
1H. | Election of Director: Stephen L. Mayo, Ph.D. | Management | For | For | |||||
1I. | Election of Director: Paul B. Rothman, M.D. | Management | For | For | |||||
1J. | Election of Director: Patricia F. Russo | Management | For | For | |||||
1K. | Election of Director: Christine E. Seidman, M.D. | Management | For | For | |||||
1L. | Election of Director: Inge G. Thulin | Management | For | For | |||||
1M. | Election of Director: Kathy J. Warden | Management | For | For | |||||
1N. | Election of Director: Peter C. Wendell | Management | For | For | |||||
2. | Non-binding advisory vote to approve the compensation of our named executive officers. | Management | For | For | |||||
3. | Ratification of the appointment of the Company’s independent registered public accounting firm for 2022. | Management | For | For | |||||
4. | Shareholder proposal regarding an independent board chairman. | Shareholder | For | Against | |||||
5. | Shareholder proposal regarding access to COVID-19 products. | Shareholder | Against | For | |||||
6. | Shareholder proposal regarding lobbying expenditure disclosure. | Shareholder | Against | For |
MEREO BIOPHARMA GROUP PLC
Security | 589492107 | Meeting Type | Annual |
Ticker Symbol | MREO | Meeting Date | 16-May-2022 |
Record Date | 01-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
O1. | That the annual report and accounts for the financial year ended 31 December 2021, together with the directors’ report and independent auditor’s report thereon, be received and adopted. | Management | For | For | |||||
O2. | That BDO LLP be re-appointed as auditors to hold office from the conclusion of the AGM until the conclusion of the next AGM at which the Company’s annual report and accounts are presented. | Management | For | For | |||||
O3. | That the directors of the Company be authorised to determine BDO LLP’s remuneration. | Management | For | For | |||||
O4. | That the directors’ remuneration report (excluding the directors’ remuneration policy), as set out in the Company’s annual report and accounts for the financial year ended 31 December 2021, be approved. | Management | For | For | |||||
O5. | That Anne Hyland be re-appointed as a director of the Company. | Management | For | For | |||||
O6. | That Dr. Pierre Jacquet be re-appointed as a director of the Company. | Management | For | For | |||||
O7. | That Dr. Deepika Pakianathan be re-appointed as a director of the Company. | Management | For | For | |||||
O8. | That Michael Wyzga be re-appointed as a director of the Company. | Management | For | For | |||||
S9. | That the new articles of association of the Company produced to the meeting and initialed by the Chairman of the meeting for the purposes of identification be adopted as the articles of association of the Company, in substitution for, and to the exclusion of, its existing articles of association. | Management | For | For |
MIRATI THERAPEUTICS, INC.
Security | 60468T105 | Meeting Type | Annual |
Ticker Symbol | MRTX | Meeting Date | 12-May-2022 |
Record Date | 15-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1. | Charles M. Baum | For | For | |||||||
2. | Bruce L.A. Carter | For | For | |||||||
3. | Julie M. Cherrington | For | For | |||||||
4. | Aaron I. Davis | For | For | |||||||
5. | Henry J. Fuchs | For | For | |||||||
6. | Faheem Hasnain | For | For | |||||||
7. | Craig Johnson | For | For | |||||||
8. | Maya Martinez-Davis | For | For | |||||||
9. | David Meek | For | For | |||||||
10. | Shalini Sharp | For | For | |||||||
2. | To approve, on an advisory basis, the compensation paid to our named executive officers as disclosed in the Proxy Statement. | Management | For | For | ||||||
3. | To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2022. | Management | For | For | ||||||
4. | To approve our 2022 Equity Incentive Plan. | Management | For | For |
MODERNA, INC.
Security | 60770K107 | Meeting Type | Annual |
Ticker Symbol | MRNA | Meeting Date | 28-Apr-2022 |
Record Date | 01-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1. | Noubar Afeyan, Ph.D. | For | For | |||||||
2. | Stéphane Bancel | For | For | |||||||
3. | François Nader, M.D. | For | For | |||||||
2. | To approve, on a non-binding, advisory basis, the compensation of our named executive officers. | Management | For | For | ||||||
3. | To ratify the appointment of Ernst & Young LLP as our registered independent public accounting firm for the year ending December 31, 2022. | Management | For | For | ||||||
4. | To vote on a shareholder proposal relating to the feasibility of transferring intellectual property. | Shareholder | For | Against |
MOLINA HEALTHCARE, INC.
Security | 60855R100 | Meeting Type | Annual |
Ticker Symbol | MOH | Meeting Date | 04-May-2022 |
Record Date | 07-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Director to hold office until the 2023 Annual Meeting: Barbara L. Brasier | Management | For | For | |||||
1B. | Election of Director to hold office until the 2023 Annual Meeting: Daniel Cooperman | Management | For | For | |||||
1C. | Election of Director to hold office until the 2023 Annual Meeting: Stephen H. Lockhart | Management | For | For | |||||
1D. | Election of Director to hold office until the 2023 Annual Meeting: Steven J. Orlando | Management | For | For | |||||
1E. | Election of Director to hold office until the 2023 Annual Meeting: Ronna E. Romney | Management | For | For | |||||
1F. | Election of Director to hold office until the 2023 Annual Meeting: Richard M. Schapiro | Management | For | For | |||||
1G. | Election of Director to hold office until the 2023 Annual Meeting: Dale B. Wolf | Management | For | For | |||||
1H. | Election of Director to hold office until the 2023 Annual Meeting: Richard C. Zoretic | Management | For | For | |||||
1I. | Election of Director to hold office until the 2023 Annual Meeting: Joseph M. Zubretsky | Management | For | For | |||||
2. | To consider and approve, on a non-binding, advisory basis, the compensation of our named executive officers. | Management | For | For | |||||
3. | To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2022. | Management | For | For |
NEUROCRINE BIOSCIENCES, INC.
Security | 64125C109 | Meeting Type | Annual |
Ticker Symbol | NBIX | Meeting Date | 18-May-2022 |
Record Date | 21-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1. | Richard F. Pops | For | For | |||||||
2. | Shalini Sharp | For | For | |||||||
3. | Stephen A. Sherwin M.D. | For | For | |||||||
2. | Advisory vote to approve the compensation paid to the Company’s named executive officers. | Management | For | For | ||||||
3. | To approve an amendment and restatement of the Company’s 2020 Equity Incentive Plan. | Management | For | For | ||||||
4. | To approve an amendment and restatement of the Company’s 2018 Employee Stock Purchase Plan. | Management | For | For | ||||||
5. | To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. | Management | For | For |
NOVAVAX, INC.
Security | 670002401 | Meeting Type | Annual |
Ticker Symbol | NVAX | Meeting Date | 16-Jun-2022 |
Record Date | 19-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Class III Director to serve for a three-year term expiring at the 2025 Annual Meeting: Rachel K. King | Management | For | For | |||||
1b. | Election of Class III Director to serve for a three-year term expiring at the 2025 Annual Meeting: James F. Young, Ph.D. | Management | For | For | |||||
2. | The approval, on an advisory basis, of the compensation paid to our Named Executive Officers. | Management | For | For | |||||
3. | Amendment and restatement of the Second Amended and Restated Certificate of Incorporation of Novavax, Inc. to eliminate the supermajority voting provisions. | Management | For | For | |||||
4. | Amendment and restatement of the Amended and Restated By-laws of Novavax, Inc. (the “By-laws”) to eliminate the supermajority voting provisions. | Management | For | For | |||||
5. | Amendment and restatement of the By-laws to permit stockholder access to proxy statement of Novavax, Inc. with respect to the nomination of directors. | Management | For | For | |||||
6. | Amendment and restatement of the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, to increase the number of shares of Common Stock available for issuance thereunder by 2,400,000 shares, and to limit the annual non- employee director compensation to $1.5 million and $1 million for the chairman of the board and board members, respectively. | Management | For | For | |||||
7. | Amendment and restatement of the Novavax, Inc. 2013 Employee Stock Purchase Plan (“ESPP”) to increase the number of shares of Common Stock available for issuance under the ESPP by 550,000 shares, such that the number of shares available for issuance is the lesser of a) 1,100,000 shares of Common Stock increased on each anniversary of the date hereof by 5% and (b) 1,650,000 shares of Common Stock. | Management | For | For | |||||
8. | Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022. | Management | For | For |
OCULIS SA
Security | N/A | Meeting Type | Written Consent |
Ticker Symbol | N/A | Meeting Date | 27-Apr-2022 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Approval of the Financial Statements 2021. | Management | For | For | |||||
2. | Appropriation of Balance Sheet Results 2021. | Management | For | For | |||||
3. | Discharge of the Members of the Board and Management. | Management | For | For | |||||
4. | Re-Election of the Board of Directors: | ||||||||
4.1 | Mr. Anthony (Tony) Rosenberg | Management | For | For | |||||
4.2 | Dr. Riad Sherif | Management | For | For | |||||
4.3 | Mr. Àrni Audunn Blöndal | Management | For | For | |||||
4.4 | Mr. Lionel Carnot | Management | For | For | |||||
4.5 | Mr. Bartosz Dzikowski | Management | For | For | |||||
4.6 | Dr. Xin (Sylvia) He | Management | For | For | |||||
4.7 | Dr. Robert Lorne Hopfner | Management | For | For | |||||
4.8 | Ms. Yi Fei (Vanessa) Huang | Management | For | For | |||||
4.9 | Dr. Henry Skinner | Management | For | For | |||||
5. | Re-Election of the Auditors PricewaterhouseCoopers SA. | Management | For | For |
OCULIS SA
Security | N/A | Meeting Type | Extraordinary General Meeting |
Ticker Symbol | N/A | Meeting Date | 30-Nov-2021 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Ordinary share capital increase | Management | For | For | |||||
2. | Conditional capital share increase | Management | For | For |
OWENS & MINOR, INC.
Security | 690732102 | Meeting Type | Annual |
Ticker Symbol | OMI | Meeting Date | 29-Apr-2022 |
Record Date | 04-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1.1 | Election of Director: Mark A. Beck | Management | For | For | |||||
1.2 | Election of Director: Gwendolyn M. Bingham | Management | For | For | |||||
1.3 | Election of Director: Kenneth Gardner-Smith | Management | For | For | |||||
1.4 | Election of Director: Robert J. Henkel | Management | For | For | |||||
1.5 | Election of Director: Stephen W. Klemash | Management | For | For | |||||
1.6 | Election of Director: Mark F. McGettrick | Management | For | For | |||||
1.7 | Election of Director: Edward A. Pesicka | Management | For | For | |||||
2. | Ratification of the appointment of KPMG LLP as the Company’s independent public accounting firm for the year ending December 31, 2022 | Management | For | For | |||||
3. | Advisory vote to approve the compensation of the Company’s named executive officers | Management | For | For | |||||
4. | Advisory vote on the frequency of a shareholder vote on the compensation of the Company’s named executive officers | Management | 1 Year | For |
PERKINELMER, INC.
Security | 714046109 | Meeting Type | Annual |
Ticker Symbol | PKI | Meeting Date | 26-Apr-2022 |
Record Date | 28-Feb-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Director for a term of one year: Peter Barrett, PhD | Management | For | For | |||||
1B. | Election of Director for a term of one year: Samuel R. Chapin | Management | For | For | |||||
1C. | Election of Director for a term of one year: Sylvie Grégoire, PharmD | Management | For | For | |||||
1D. | Election of Director for a term of one year: Alexis P. Michas | Management | For | For | |||||
1E. | Election of Director for a term of one year: Prahlad R. Singh, PhD | Management | For | For | |||||
1F. | Election of Director for a term of one year: Michel Vounatsos | Management | For | For | |||||
1G. | Election of Director for a term of one year: Frank Witney, PhD | Management | For | For | |||||
1H. | Election of Director for a term of one year: Pascale Witz | Management | For | For | |||||
2. | To ratify the selection of Deloitte & Touche LLP as PerkinElmer’s independent registered public accounting firm for the current fiscal year. | Management | For | For | |||||
3. | To approve, by non-binding advisory vote, our executive compensation. | Management | For | For |
PERRIGO COMPANY PLC
Security | G97822103 | Meeting Type | Annual |
Ticker Symbol | PRGO | Meeting Date | 06-May-2022 |
Record Date | 07-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Director to hold office until the 2023 Annual General Meeting of Shareholders: Bradley A. Alford | Management | For | For | |||||
1B. | Election of Director to hold office until the 2023 Annual General Meeting of Shareholders: Orlando D. Ashford | Management | For | For | |||||
1C. | Election of Director to hold office until the 2023 Annual General Meeting of Shareholders: Katherine C. Doyle | Management | For | For | |||||
1D. | Election of Director to hold office until the 2023 Annual General Meeting of Shareholders: Adriana Karaboutis | Management | For | For | |||||
1E. | Election of Director to hold office until the 2023 Annual General Meeting of Shareholders: Murray S. Kessler | Management | For | For | |||||
1F. | Election of Director to hold office until the 2023 Annual General Meeting of Shareholders: Jeffrey B. Kindler | Management | For | For | |||||
1G. | Election of Director to hold office until the 2023 Annual General Meeting of Shareholders: Erica L. Mann | Management | For | For | |||||
1H. | Election of Director to hold office until the 2023 Annual General Meeting of Shareholders: Donal O’Connor | Management | For | For | |||||
1I. | Election of Director to hold office until the 2023 Annual General Meeting of Shareholders: Geoffrey M. Parker | Management | For | For | |||||
1J. | Election of Director to hold office until the 2023 Annual General Meeting of Shareholders: Theodore R. Samuels | Management | For | For | |||||
2. | Ratify, in a non-binding advisory vote, the appointment of Ernst & Young LLP as the Company’s independent auditor, and authorize, in a binding vote, the Board of Directors, acting through the Audit Committee, to fix the remuneration of the auditor | Management | For | For | |||||
3. | Advisory vote on executive compensation | Management | For | For | |||||
4. | Amend the Company’s Long-Term Incentive Plan | Management | For | For | |||||
5. | Renew the Board’s authority to issue shares under Irish law | Management | For | For | |||||
6. | Renew the Board’s authority to opt-out of statutory pre- emption rights under Irish law | Management | For | For |
PFIZER, INC.
Security | 717081103 | Meeting Type | Annual |
Ticker Symbol | PFE | Meeting Date | 28-Apr-2022 |
Record Date | 02-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Director: Ronald E. Blaylock | Management | For | For | |||||
1B. | Election of Director: Albert Bourla | Management | For | For | |||||
1C. | Election of Director: Susan Desmond-Hellmann | Management | For | For | |||||
1D. | Election of Director: Joseph J. Echevarria | Management | For | For | |||||
1E. | Election of Director: Scott Gottlieb | Management | For | For | |||||
1F. | Election of Director: Helen H. Hobbs | Management | For | For | |||||
1G. | Election of Director: Susan Hockfield | Management | For | For | |||||
1H. | Election of Director: Dan R. Littman | Management | For | For | |||||
1I. | Election of Director: Shantanu Narayen | Management | For | For | |||||
1J. | Election of Director: Suzanne Nora Johnson | Management | For | For | |||||
1K. | Election of Director: James Quincey | Management | For | For | |||||
1L. | Election of Director: James C. Smith | Management | For | For | |||||
2. | Ratify the selection of KPMG LLP as independent registered public accounting firm for 2022 | Management | For | For | |||||
3. | 2022 advisory approval of executive compensation | Management | For | For | |||||
4. | Shareholder proposal regarding amending proxy access | Shareholder | Against | For | |||||
5. | Shareholder proposal regarding report on political expenditures congruency | Shareholder | Against | For | |||||
6. | Shareholder proposal regarding report on transfer of intellectual property to potential COVID-19 manufacturers | Shareholder | Against | For | |||||
7. | Shareholder proposal regarding report on board oversight of risks related to anticompetitive practices | Shareholder | Against | For | |||||
8. | Shareholder proposal regarding report on public health costs of protecting vaccine technology | Shareholder | Against | For |
PRAXIS PRECISION MEDICINES, INC.
Security | 74006W108 | Meeting Type | Annual |
Ticker Symbol | PRAX | Meeting Date | 26-May-2022 |
Record Date | 28-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Class II Director to serve until the 2025 Annual Meeting: Jeffrey Chodakewitz, M.D. | Management | For | For | |||||
1B. | Election of Class II Director to serve until the 2025 Annual Meeting: Merit Cudkowicz, M.D. | Management | For | For | |||||
1C. | Election of Class II Director to serve until the 2025 Annual Meeting: Stefan Vitorovic | Management | For | For | |||||
2. | To ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. | Management | For | For | |||||
3. | To approve on a non-binding advisory basis, the compensation of the named executive officers as disclosed in the Company’s proxy statement for the 2022 Annual Meeting pursuant to the applicable compensation disclosure rules of the SEC, including the compensation tables and narrative discussion. | Management | For | For | |||||
4. | To approve on a non-binding advisory basis the frequency of future advisory votes on the compensation of the Company’s named executive officers. | Management | 1 Year | Against |
PRECISION BIOSCIENCES, INC.
Security | 74019P108 | Meeting Type | Annual |
Ticker Symbol | DTIL | Meeting Date | 10-May-2022 |
Record Date | 15-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1. | Kevin J. Buehler | For | For | |||||||
2. | Shari Lisa Piré | For | For | |||||||
2 | Ratification of the appointment of Deloitte & Touche LLP as Precision’s independent registered public accounting firm for 2022. | Management | For | For |
PRIOTHERA LTD.
Security | N/A | Meeting Type | Extraordinary General Meeting |
Ticker Symbol | N/A | Meeting Date | 28-Sep-2021 |
Record Date | N/A |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Partial waiver of tranche 2 milestone condition | Management | For | For |
PYXIS ONCOLOGY, INC.
Security | 747324101 | Meeting Type | Annual |
Ticker Symbol | PYXS | Meeting Date | 13-Jun-2022 |
Record Date | 20-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1.1 | Election of Class I Director: Darren Cline | Management | For | For | |||||
2. | Ratification of the Appointment of Ernst & Young LLP as our Independent Registered Public Accounting Firm for the Fiscal Year ending December 31, 2022 | Management | For | For |
RALLYBIO CORPORATION
Security | 75120L100 | Meeting Type | Annual |
Ticker Symbol | RLYB | Meeting Date | 24-May-2022 |
Record Date | 30-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1.1 | Election of Class I Director: Martin W. Mackay | Management | For | For | |||||
1.2 | Election of Class I Director: Kush M. Parmar | Management | For | For | |||||
1.3 | Election of Class I Director: Paula Soteropoulos | Management | For | For | |||||
2. | Ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm. | Management | For | For |
REGENERON PHARMACEUTICALS, INC.
Security | 75886F107 | Meeting Type | Annual |
Ticker Symbol | REGN | Meeting Date | 10-Jun-2022 |
Record Date | 12-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director: Bonnie L. Bassler, Ph.D. | Management | For | For | |||||
1b. | Election of Director: Michael S. Brown, M.D. | Management | For | For | |||||
1c. | Election of Director: Leonard S. Schleifer, M.D., Ph.D. | Management | For | For | |||||
1d. | Election of Director: George D. Yancopoulos, M.D., Ph.D. | Management | For | For | |||||
2. | Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. | Management | For | For | |||||
3. | Proposal to approve, on an advisory basis, executive compensation. | Management | For | For |
REPLIMUNE GROUP, INC.
Security | 76029N106 | Meeting Type | Annual |
Ticker Symbol | REPL | Meeting Date | 08-Sep-2021 |
Record Date | 15-Jul-2021 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1. | Robert Coffin, Ph.D. | For | For | |||||||
2. | Hyam Levitsky, M.D. | For | For | |||||||
3. | Dieter Weinand | For | For | |||||||
2. | To ratify the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for Replimune Group, Inc. for the fiscal year ending March 31, 2022. | Management | For | For |
SAREPTA THERAPEUTICS, INC.
Security | 803607100 | Meeting Type | Annual |
Ticker Symbol | SRPT | Meeting Date | 02-Jun-2022 |
Record Date | 08-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1.1 | Election of Class I Director to hold office until the 2024 Annual meeting: Kathryn Boor, Ph.D. | Management | For | For | |||||
1.2 | Election of Class I Director to hold office until the 2024 Annual meeting: Michael Chambers | Management | For | For | |||||
1.3 | Election of Class I Director to hold office until the 2024 Annual meeting: Douglas S. Ingram | Management | For | For | |||||
1.4 | Election of Class I Director to hold office until the 2024 Annual meeting: Hans Wigzell, M.D., Ph.D. | Management | For | For | |||||
2. | To hold an advisory vote to approve, on a non-binding basis, named executive officer compensation. | Management | For | For | |||||
3. | To approve an amendment to the Company’s 2018 Equity Incentive Plan (the “2018 Plan”) to increase the maximum aggregate number of shares of common stock that may be issued pursuant to awards granted under the 2018 Plan by 2,500,000 shares to 10,687,596 shares. | Management | For | For | |||||
4. | To ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the current year ending December 31, 2022. | Management | For | For |
SCHOLAR ROCK HOLDING CORPORATION
Security | 80706P103 | Meeting Type | Annual |
Ticker Symbol | SRRK | Meeting Date | 26-May-2022 |
Record Date | 04-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1. | N. K. Mahanthappa Ph.D. | For | For | |||||||
2. | Joshua Reed | For | For | |||||||
2. | To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. | Management | For | For |
SEAGEN, INC.
Security | 81181C104 | Meeting Type | Annual |
Ticker Symbol | SGEN | Meeting Date | 13-May-2022 |
Record Date | 17-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Class III Director: Ted W. Love, M.D. | Management | For | For | |||||
1B. | Election of Class III Director: Daniel G. Welch | Management | For | For | |||||
2. | Approve, on an advisory basis, the compensation of Seagen’s named executive officers as disclosed in the accompanying proxy statement. | Management | For | For | |||||
3. | Ratify the appointment of PricewaterhouseCoopers LLP as Seagen’s independent registered public accounting firm for the fiscal year ending December 31, 2022. | Management | For | For |
SPECTRUM PHARMACEUTICALS, INC.
Security | 84763A108 | Meeting Type | Annual |
Ticker Symbol | SPPI | Meeting Date | 21-Jun-2022 |
Record Date | 25-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1.1 | Election of Director: William L. Ashton | Management | For | For | |||||
1.2 | Election of Director: Brittany K. Bradrick | Management | For | For | |||||
1.3 | Election of Director: Seth H.Z. Fischer | Management | For | For | |||||
1.4 | Election of Director: Juhyun Lim | Management | For | For | |||||
1.5 | Election of Director: Thomas J. Riga | Management | For | For | |||||
1.6 | Election of Director: Jeffrey L. Vacirca | Management | For | For | |||||
2. | To approve, on a non-binding advisory basis, the compensation of our named executive officers, as disclosed in the Compensation Discussion and Analysis section of the Proxy Statement. | Management | For | For | |||||
3. | To approve the adoption of a proposed amended and restated Spectrum Pharmaceuticals, Inc. 2018 Long- Term Incentive Plan. | Management | For | For |
STERIS PLC
Security | G8473T100 | Meeting Type | Annual |
Ticker Symbol | STE | Meeting Date | 29-Jul-2021 |
Record Date | 01-Jun-2021 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Re-election of Director: Richard C. Breeden | Management | For | For | |||||
1B. | Re-election of Director: Daniel A. Carestio | Management | For | For | |||||
1C. | Re-election of Director: Cynthia L. Feldmann | Management | For | For | |||||
1D. | Re-election of Director: Christopher Holland | Management | For | For | |||||
1E. | Re-election of Director: Dr. Jacqueline B. Kosecoff | Management | For | For | |||||
1F. | Re-election of Director: Paul E. Martin | Management | For | For | |||||
1G. | Re-election of Director: Dr. Nirav R. Shah | Management | For | For | |||||
1H. | Re-election of Director: Dr. Mohsen M. Sohi | Management | For | For | |||||
1I. | Re-election of Director: Dr. Richard M. Steeves | Management | For | For | |||||
2. | To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending March 31, 2022. | Management | For | For | |||||
3. | To appoint Ernst & Young Chartered Accountants as the Company’s Irish statutory auditor under the Act to hold office until the conclusion of the Company’s next Annual General Meeting. | Management | For | For | |||||
4. | To authorize the Directors of the Company or the Audit Committee to determine the remuneration of Ernst & Young Chartered Accountants as the Company’s Irish statutory auditor. | Management | For | For | |||||
5. | To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed pursuant to the disclosure rules of the Securities and Exchange Commission, including the Compensation Discussion and Analysis and the tabular and narrative disclosure contained in the Company’s proxy statement dated June 14, 2021. | Management | For | For |
STRYKER CORPORATION
Security | 863667101 | Meeting Type | Annual |
Ticker Symbol | SYK | Meeting Date | 04-May-2022 |
Record Date | 07-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A) | Election of Director: Mary K. Brainerd | Management | For | For | |||||
1B) | Election of Director: Giovanni Caforio, M.D. | Management | For | For | |||||
1C) | Election of Director: Srikant M. Datar, Ph.D. | Management | For | For | |||||
1D) | Election of Director: Allan C. Golston (Lead Independent Director) | Management | For | For | |||||
1E) | Election of Director: Kevin A. Lobo (Chair of the Board, Chief Executive Officer and President) | Management | For | For | |||||
1F) | Election of Director: Sherilyn S. McCoy | Management | For | For | |||||
1G) | Election of Director: Andrew K. Silvernail | Management | For | For | |||||
1H) | Election of Director: Lisa M. Skeete Tatum | Management | For | For | |||||
1I) | Election of Director: Ronda E. Stryker | Management | For | For | |||||
1J) | Election of Director: Rajeev Suri | Management | For | For | |||||
2) | Ratification of Appointment of our Independent Registered Public Accounting Firm. | Management | For | For | |||||
3) | Advisory Vote to Approve Named Executive Officer Compensation. | Management | For | For | |||||
4) | Shareholder Proposal to Amend Proxy Access Terms. | Shareholder | Against | For |
SUTRO BIOPHARMA, INC.
Security | 869367102 | Meeting Type | Annual |
Ticker Symbol | STRO | Meeting Date | 06-Jun-2022 |
Record Date | 12-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1. | Michael Dybbs, Ph.D. | For | For | |||||||
2. | John G. Freund, M.D. | For | For | |||||||
3. | Heidi Hunter | For | For | |||||||
4. | Jon Wigginton, M.D. | For | For | |||||||
2. | To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022. | Management | For | For | ||||||
3. | To approve, on a non-binding, advisory basis, the compensation of our named executive officers. | Management | For | For | ||||||
4. | To determine, on a non-binding, advisory basis, the frequency of future non-binding, advisory votes on the compensation of the Company’s named executive officers. | Management | 1 Year | For |
SYNEOS HEALTH, INC.
Security | 87166B102 | Meeting Type | Annual |
Ticker Symbol | SYNH | Meeting Date | 25-May-2022 |
Record Date | 28-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Director: Todd M. Abbrecht | Management | For | For | |||||
1B. | Election of Director: John M. Dineen | Management | For | For | |||||
1C. | Election of Director: William E. Klitgaard | Management | For | For | |||||
1D. | Election of Director: David S. Wilkes, M.D. | Management | For | For | |||||
2. | To approve an amendment to the Certificate of Incorporation to phase-out the classified board structure and provide that all directors elected at or after the 2025 annual meeting of stockholders be elected on an annual basis. | Management | For | For | |||||
3. | To approve, on an advisory (nonbinding) basis, our executive compensation. | Management | For | For | |||||
4. | To approve, on an advisory (nonbinding) basis, the frequency of future stockholder advisory votes on executive compensation. | Management | 1 Year | For | |||||
5. | To ratify the appointment of the Company’s independent auditors Deloitte & Touche LLP. | Management | For | For |
TCR2 THERAPEUTICS, INC.
Security | 87808K106 | Meeting Type | Annual |
Ticker Symbol | TCRR | Meeting Date | 22-Oct-2021 |
Record Date | 23-Aug-2021 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1. | Garry E. Menzel, Ph.D. | For | For | |||||||
2. | Ansbert Gadicke, M.D. | For | For | |||||||
3. | Neil Gibson, Ph.D. | For | For | |||||||
2. | To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021. | Management | For | For |
TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Security | 881624209 | Meeting Type | Annual |
Ticker Symbol | TEVA | Meeting Date | 23-Jun-2022 |
Record Date | 16-May-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director: Amir Elstein | Management | For | For | |||||
1b. | Election of Director: Roberto A. Mignone | Management | For | For | |||||
1c. | Election of Director: Dr. Perry D. Nisen | Management | For | For | |||||
1d. | Election of Director: Dr. Tal Zaks | Management | For | For | |||||
2. | To approve, on a non-binding advisory basis, the compensation for Teva’s named executive officers. | Management | For | For | |||||
3. | To approve Teva’s Compensation Policy with respect to the Terms of Office and Employment of Teva’s Executive Officers and Directors. | Management | For | For | |||||
3A. | Regarding proposal 3, please indicate when you vote whether or not you are a controlling shareholder of Teva and whether or not you have a personal benefit or other interest in this proposal* Mark “for” = yes or “against” = no. | Management | Against | N/A | |||||
4. | To approve amendments to Teva’s Articles of Association. | Management | For | For | |||||
5. | To appoint Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva’s independent registered public accounting firm until Teva’s 2023 annual meeting of shareholders. | Management | For | For | |||||
THERMO FISHER SCIENTIFIC, INC.
Security | 883556102 | Meeting Type | Annual |
Ticker Symbol | TMO | Meeting Date | 18-May-2022 |
Record Date | 25-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of director: Marc N. Casper | Management | For | For | |||||
1B. | Election of director: Nelson J. Chai | Management | For | For | |||||
1C. | Election of director: Ruby R. Chandy | Management | For | For | |||||
1D. | Election of director: C. Martin Harris | Management | For | For | |||||
1E. | Election of director: Tyler Jacks | Management | For | For | |||||
1F. | Election of director: R. Alexandra Keith | Management | For | For | |||||
1G. | Election of director: Jim P. Manzi | Management | For | For | |||||
1H. | Election of director: James C. Mullen | Management | For | For | |||||
1I. | Election of director: Lars R. Sorensen | Management | For | For | |||||
1J. | Election of director: Debora L. Spar | Management | For | For | |||||
1K. | Election of director: Scott M. Sperling | Management | For | For | |||||
1L. | Election of director: Dion J. Weisler | Management | For | For | |||||
2. | An advisory vote to approve named executive officer compensation. | Management | For | For | |||||
3. | Ratification of the Audit Committee’s selection of PricewaterhouseCoopers LLP as the Company’s independent auditors for 2022. | Management | For | For |
THESEUS PHARMACEUTICALS, INC.
Security | 88369M101 | Meeting Type | Annual |
Ticker Symbol | THRX | Meeting Date | 10-Jun-2022 |
Record Date | 14-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1. | Iain D. Dukes | For | For | |||||||
2. | Kathy Yi | For | For | |||||||
2. | To ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022. | Management | For | For |
TRAVERE THERAPEUTICS, INC.
Security | 89422G107 | Meeting Type | Annual |
Ticker Symbol | TVTX | Meeting Date | 11-May-2022 |
Record Date | 18-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1. | Roy Baynes | For | For | |||||||
2. | Suzanne Bruhn | For | For | |||||||
3. | Timothy Coughlin | For | For | |||||||
4. | Eric Dube | For | For | |||||||
5. | Gary Lyons | For | For | |||||||
6. | Jeffrey Meckler | For | For | |||||||
7. | John Orwin | For | For | |||||||
8. | Sandra Poole | For | For | |||||||
9. | Ron Squarer | For | For | |||||||
10. | Ruth Williams-Brinkley | For | For | |||||||
2. | To approve the Company’s 2018 Equity Incentive Plan, as amended, to, among other items, increase the number of shares of common stock authorized for issuance thereunder by 2,000,000 shares. | Management | For | For | ||||||
3. | To approve, on an advisory basis, the compensation of the Company’s named executive officers. | Management | For | For | ||||||
4. | To ratify the selection of BDO USA, LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022. | Management | For | For |
TRILLIUM THERAPEUTICS, INC.
Security | 89620X506 | Meeting Type | Special |
Ticker Symbol | TRIL | Meeting Date | 26-Oct-2021 |
Record Date | 24-Sep-2021 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | To consider and, if deemed advisable, pass, with or without variation, a special resolution, the full text of which is set forth in Appendix B to the accompanying Management Information Circular and Proxy Statement of Trillium dated September 27, 2021 (the “Information Circular”), approving a statutory arrangement (the “Arrangement”) under Division 5 of Part 9 of the Business Corporations Act (British Columbia) involving Trillium, all as more particularly described in the Information Circular. | Management | For | For | |||||
2. | To consider and, if deemed advisable, pass an advisory (non- binding) resolution on specified compensation that may become payable to the named executive officers of Trillium in connection with the Arrangement, all as more particularly described in the Information Circular. | Management | For | For |
TSCAN THERAPEUTICS, INC.
Security | 89854M101 | Meeting Type | Annual |
Ticker Symbol | TCRX | Meeting Date | 01-Jun-2022 |
Record Date | 12-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1. | Timothy Barberich | For | For | |||||||
2. | Stephen Biggar | For | For | |||||||
2. | To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022 | Management | For | For |
ULTRAGENYX PHARMACEUTICAL INC.
Security | 90400D108 | Meeting Type | Annual |
Ticker Symbol | RARE | Meeting Date | 24-Jun-2022 |
Record Date | 26-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director: Lars Ekman, M.D., Ph.D. | Management | For | For | |||||
1b. | Election of Director: Matthew K. Fust | Management | For | For | |||||
1c. | Election of Director: Amrit Ray, M.D. | Management | For | For | |||||
2. | Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022. | Management | For | For | |||||
3. | Advisory (non-binding) vote to approve the compensation of our named executive officers. | Management | For | For | |||||
4. | Advisory (non-binding) vote on the frequency of future advisory votes to approve executive compensation. | Management | 1 Year | For |
UNIQURE N.V.
Security | N90064101 | Meeting Type | Special |
Ticker Symbol | QURE | Meeting Date | 21-Oct-2021 |
Record Date | 23-Sep-2021 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Appointment of Rachelle Jacques as a non-executive director. | Management | For | For |
UNIQURE N.V.
Security | N90064101 | Meeting Type | Annual |
Ticker Symbol | QURE | Meeting Date | 14-Jun-2022 |
Record Date | 17-May-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Resolution to adopt the 2021 Dutch statutory annual accounts and treatment of the results. | Management | For | For | |||||
2. | Resolution to discharge liability of the members of the Board. | Management | For | For | |||||
3. | Resolution to reappoint Matthew Kapusta as executive director. | Management | For | For | |||||
4. | Resolution to reappoint Robert Gut as non-executive director. | Management | For | For | |||||
5. | Resolution to renew the designation of the Board as the competent body to issue ordinary shares and grant rights to subscribe for ordinary shares. | Management | For | For | |||||
6. | Resolution to reauthorize the Board to exclude or limit preemptive rights upon the issuance of ordinary shares. | Management | For | For | |||||
7. | Resolution to reauthorize the Board to repurchase ordinary shares. | Management | For | For | |||||
8. | Resolution to appoint KPMG as external auditor of the Company for the 2022 financial year. | Management | For | For | |||||
9. | Resolution to approve, on an advisory basis, the compensation of the named executive officers of the Company. | Management | For | For |
UNITED THERAPEUTICS CORPORATION
Security | 91307C102 | Meeting Type | Special |
Ticker Symbol | UTHR | Meeting Date | 30-Sep-2021 |
Record Date | 10-Aug-2021 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Approval of an amendment to our Restated Certificate of Incorporation to become a public benefit corporation. | Management | Abstain | Against |
UNITED THERAPEUTICS CORPORATION
Security | 91307C102 | Meeting Type | Annual |
Ticker Symbol | UTHR | Meeting Date | 27-Jun-2022 |
Record Date | 28-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director: Christopher Causey | Management | For | For | |||||
1b. | Election of Director: Richard Giltner | Management | For | For | |||||
1c. | Election of Director: Katherine Klein | Management | For | For | |||||
1d. | Election of Director: Ray Kurzweil | Management | For | For | |||||
1e. | Election of Director: Linda Maxwell | Management | For | For | |||||
1f. | Election of Director: Nilda Mesa | Management | For | For | |||||
1g. | Election of Director: Judy Olian | Management | For | For | |||||
1h. | Election of Director: Martine Rothblatt | Management | For | For | |||||
1i. | Election of Director: Louis Sullivan | Management | For | For | |||||
2. | Advisory resolution to approve executive compensation. | Management | For | For | |||||
3. | Approval of the amendment and restatement of the United Therapeutics Corporation Amended and Restated 2015 Stock Incentive Plan. | Management | For | For | |||||
4. | Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for 2022. | Management | For | For |
UNITEDHEALTH GROUP, INC.
Security | 91324P102 | Meeting Type | Annual |
Ticker Symbol | UNH | Meeting Date | 06-Jun-2022 |
Record Date | 08-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1a. | Election of Director: Timothy P. Flynn | Management | For | For | |||||
1b. | Election of Director: Paul R. Garcia | Management | For | For | |||||
1c. | Election of Director: Stephen J. Hemsley | Management | For | For | |||||
1d. | Election of Director: Michele J. Hooper | Management | For | For | |||||
1e. | Election of Director: F. William McNabb III | Management | For | For | |||||
1f. | Election of Director: Valerie C. Montgomery Rice, M.D. | Management | For | For | |||||
1g. | Election of Director: John H. Noseworthy, M.D. | Management | For | For | |||||
1h. | Election of Director: Andrew Witty | Management | For | For | |||||
2. | Advisory approval of the Company’s executive compensation. | Management | For | For | |||||
3. | Ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the year ending December 31, 2022. | Management | For | For | |||||
4. | If properly presented at the 2022 Annual Meeting of Shareholders, the shareholder proposal seeking shareholder ratification of termination pay. | Shareholder | Against | For | |||||
5. | If properly presented at the 2022 Annual Meeting of Shareholders, the shareholder proposal regarding political contributions congruency report. | Shareholder | Against | For |
VECTIVBIO HOLDING AG
Security | H9060V101 | Meeting Type | Special |
Ticker Symbol | VECT | Meeting Date | 02-Sep-2021 |
Record Date | 06-Aug-2021 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | Paul Rutherford Carter - The Board of Directors proposes to elect Paul Rutherford Carter as a new member of the Board of Directors for a term of office until completion of the 2022 Annual General Meeting of VectivBio Holding AG. | Management | For | For | |||||
2. | Dr. Murray Willis Stewart - The Board of Directors proposes to elect Dr. Murray Willis Stewart as a new member of the Board of Directors for a term of office until completion of the 2022 Annual General Meeting of VectivBio Holding AG. | Management | For | For | |||||
VECTIVBIO HOLDING AG
Security | H9060V101 | Meeting Type | Annual |
Ticker Symbol | VECT | Meeting Date | 30-Jun-2022 |
Record Date | 20-May-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1.1 | 2021 Statutory Financial Statements and Consolidated Financial Statements - The Board of Directors proposes that the Statutory Financial Statements and the Consolidated Financial Statements for the financial year 2021 be approved. | Management | For | For | |||||
1.2 | 2021 Compensation Report - The Board of Directors proposes that the 2021 Compensation Report be endorsed in a non-binding advisory vote. | Management | For | For | |||||
2. | 2021 Financial Results - The Board of Directors proposes that the loss of the Company be carried forward as follows: Loss carried forward from the financial year 2020 CHF -8,709,776 Loss for the financial year 2021 CHF - 19,725,299 Loss to be carried forward CHF -28,435,075. | Management | For | For | |||||
3. | Discharge of the Board of Directors and of the Executive Committee - The Board of Directors proposes that all members of the Board of Directors and of the Executive Committee be discharged from liability for their activities during the financial year 2021. | Management | For | For | |||||
4.1 | Thomas Woiwode - The Board of Directors proposes to re-elect Thomas Woiwode as Chairman and member of the Board of Directors for a term of office until completion of the 2023 Annual General Meeting. | Management | For | For | |||||
4.2 | Sandip Kapadia - The Board of Directors proposes to re- elect Sandip Kapadia as member of the Board of Directors for a term of office until completion of the 2023 Annual General Meeting. | Management | For | For | |||||
4.3 | Chahra Louafi - The Board of Directors proposes to re- elect Chahra Louafi as member of the Board of Directors for a term of office until completion of the 2023 Annual General Meeting. | Management | For | For | |||||
4.4 | Paul Rutherford Carter - The Board of Directors proposes to re- elect Paul Rutherford Carter as member of the Board of Directors for a term of office until completion of the 2023 Annual General Meeting. | Management | For | For | |||||
4.5 | Luca Santarelli - The Board of Directors proposes to re- elect Luca Santarelli as member of the Board of Directors for a term of office until completion of the 2023 Annual General Meeting. | Management | For | For | |||||
4.6 | Hans Schikan - The Board of Directors proposes to re- elect Hans Schikan as member of the Board of Directors for a term of office until completion of the 2023 Annual General Meeting. | Management | For | For | |||||
4.7 | Murray Willis Stewart - The Board of Directors proposes to re- elect Murray Willis Stewart as member of the Board of Directors for a term of office until completion of the 2023 Annual General Meeting. | Management | For | For | |||||
5.1 | Paul Rutherford Carter - The Board of Directors proposes to re- elect Paul Rutherford Carter as member of the Compensation Committee for a term of office until completion of the 2023 Annual General Meeting. | Management | For | For | |||||
5.2 | Murray Willis Stewart - The Board of Directors proposes to re- elect Murray Willis Stewart as member of the Compensation Committee for a term of office until completion of the 2023 Annual General Meeting. | Management | For | For | |||||
5.3 | Thomas Woiwode - The Board of Directors proposes to re-elect Thomas Woiwode as member of the Compensation Committee for a term of office until completion of the 2023 Annual General Meeting. | Management | For | For | |||||
6. | Re-election of the Statutory Auditors - The Board of Directors proposes that Ernst & Young AG, in Basel, Switzerland, be re- elected as the Company’s statutory auditors for the financial year 2022. | Management | For | For | |||||
7. | Re-election of the Independent Proxy - The Board of Directors proposes that Buis Bürgi AG, Zürich, Switzerland, be re-elected as independent proxy for a term of office until completion of the 2023 Annual General Meeting. | Management | For | For | |||||
8.1 | Maximum Aggregate Amount of Compensation of the Board of Directors - The Board of Directors proposes that a maximum aggregate amount of compensation of the Board of Directors for the period from the 2022 Annual General Meeting to the 2023 Annual General Meeting of CHF 1,500,000 be approved. | Management | For | For | |||||
8.2 | Maximum Aggregate Amount of Compensation of the Executive Committee - The Board of Directors proposes that a maximum aggregate amount of compensation of the Executive Committee for the financial year 2023 of CHF 16,300,000 be approved. | Management | For | For | |||||
9.1 | Increase and Renewal of Authorized Share Capital - The Board of Directors proposes that the Company’s authorized share capital be increased and renewed to CHF 992,218.00 to enable the Board of Directors to issue up to 19,844,360 new registered shares with a par value of CHF 0.05 each until June 30, 2024, and to explicitly authorize the Board of Directors to determine as type of contribution for the capital increase(s) out of the authorized share capital any legally permitted type of ...(due to space limits, see proxy material for full proposal). | Management | For | For | |||||
9.2 | Increase of the Conditional Share Capital for Participation Programs - The Board of Directors proposes that the Company’s conditional share capital for participation programs be increased by CHF 159,825.75 to the maximum amount of CHF 541,332.00, allowing the issuance of up to 10,826,640 registered shares with a par value of CHF 0.05 each, and, accordingly, to amend article 3b (Conditional Share Capital for Participation Programs), paragraph 1, of the Articles of Association as ...(due to space limits, see proxy material for full proposal). | Management | For | For |
VERTEX PHARMACEUTICALS INCORPORATED
Security | 92532F100 | Meeting Type | Annual |
Ticker Symbol | VRTX | Meeting Date | 18-May-2022 |
Record Date | 24-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Director: Sangeeta Bhatia | Management | For | For | |||||
1B. | Election of Director: Lloyd Carney | Management | For | For | |||||
1C. | Election of Director: Alan Garber | Management | For | For | |||||
1D. | Election of Director: Terrence Kearney | Management | For | For | |||||
1E. | Election of Director: Reshma Kewalramani | Management | For | For | |||||
1F. | Election of Director: Yuchun Lee | Management | For | For | |||||
1G. | Election of Director: Jeffrey Leiden | Management | For | For | |||||
1H. | Election of Director: Margaret McGlynn | Management | For | For | |||||
1I. | Election of Director: Diana McKenzie | Management | For | For | |||||
1J. | Election of Director: Bruce Sachs | Management | For | For | |||||
1K. | Election of Director: Suketu Upadhyay | Management | For | For | |||||
2. | Ratification of Ernst & Young LLP as independent Registered Public Accounting firm for the year ending December 31, 2022. | Management | For | For | |||||
3. | Advisory vote to approve named executive office compensation. | Management | For | For | |||||
4. | Approval of an amendment and restatement of our 2013 Stock and Option Plan to increase the number of shares authorized for issuance under this plan by 13.5 million shares. | Management | For | For |
VYNE THERAPEUTICS, INC.
Security | 92941V209 | Meeting Type | Annual |
Ticker Symbol | VYNE | Meeting Date | 19-Jul-2021 |
Record Date | 27-May-2021 |
Item | Proposal | Proposed by | Vote | For/Against Management | ||||||
1. | DIRECTOR | Management | ||||||||
1. | David Domzalski | For | For | |||||||
2. | Patrick LePore | For | For | |||||||
2. | To ratify the selection by the Audit Committee of the Company’s Board of Directors of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021. | Management | For | For | ||||||
3. | To approve and adopt an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 75,000,000 to 150,000,000. | Management | For | For |
WATERS CORPORATION
Security | 941848103 | Meeting Type | Annual |
Ticker Symbol | WAT | Meeting Date | 24-May-2022 |
Record Date | 25-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1.1 | Election of Director: Dr. Udit Batra, Ph.D. | Management | For | For | |||||
1.2 | Election of Director: Linda Baddour | Management | For | For | |||||
1.3 | Election of Director: Edward Conard | Management | For | For | |||||
1.4 | Election of Director: Dr. Pearl S. Huang, Ph.D. | Management | For | For | |||||
1.5 | Election of Director: Wei Jiang | Management | For | For | |||||
1.6 | Election of Director: Christopher A. Kuebler | Management | For | For | |||||
1.7 | Election of Director: Dr. Flemming Ornskov, M.D., M.P.H. | Management | For | For | |||||
1.8 | Election of Director: Thomas P. Salice | Management | For | For | |||||
2. | To ratify the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. | Management | For | For | |||||
3. | To approve, by non-binding vote, executive compensation. | Management | For | For |
XENCOR, INC.
Security | 98401F105 | Meeting Type | Annual |
Ticker Symbol | XNCR | Meeting Date | 23-Jun-2022 |
Record Date | 25-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1.1 | Election of Director: Bassil I. Dahiyat, Ph.D. | Management | For | For | |||||
1.2 | Election of Director: Ellen G. Feigal, M.D. | Management | For | For | |||||
1.3 | Election of Director: Kevin C. Gorman, Ph. D. | Management | For | For | |||||
1.4 | Election of Director: Kurt A. Gustafson | Management | For | For | |||||
1.5 | Election of Director: Yujiro S. Hata | Management | For | For | |||||
1.6 | Election of Director: A. Bruce Montgomery, M.D. | Management | For | For | |||||
1.7 | Election of Director: Richard J. Ranieri | Management | For | For | |||||
1.8 | Election of Director: Dagmar Rosa-Bjorkeson | Management | For | For | |||||
2. | To ratify the selection by the Audit Committee of the Board of Directors of RSM US LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022. | Management | For | For | |||||
3. | To hold a non-binding advisory vote on the compensation of the Company’s named executive officers, as disclosed in the proxy statement. | Management | For | For |
ZAI LAB LTD
Security | 98887Q104 | Meeting Type | Special |
Ticker Symbol | ZLAB | Meeting Date | 28-Mar-2022 |
Record Date | 18-Feb-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1. | THAT, the subdivision of each issued and unissued ordinary shares of the Company with a par value of US$0.00006 each into 10 ordinary shares with a par value of US$0.000006 each with effect from March 30, 2022, subject to and conditional upon the Listing Committee of The Stock Exchange of Hong Kong Limited granting the listing of, and permission to deal in, (i) the Subdivided Ordinary Shares (as defined below) (ii) any Subdivided Ordinary Shares which may be issued upon exercise of ...(due to space limits,see proxy material for full proposal). | Management | For | For |
ZAI LAB LTD
Security | 98887Q104 | Meeting Type | Annual |
Ticker Symbol | ZLAB | Meeting Date | 22-Jun-2022 |
Record Date | 25-Apr-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
O1 | An ordinary resolution to re-elect Samantha (Ying) Du to serve as a director until the 2023 annual general meeting of shareholders and until her successor is duly elected and qualified, subject to her earlier resignation or removal. | Management | For | For | |||||
O2 | An ordinary resolution to re-elect Kai-Xian Chen to serve as a director until the 2023 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal. | Management | For | For | |||||
O3 | An ordinary resolution to re-elect John D. Diekman to serve as a director until the 2023 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal. | Management | For | For | |||||
O4 | An ordinary resolution to re-elect Richard Gaynor to serve as a director until the 2023 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal. | Management | For | For | |||||
O5 | An ordinary resolution to re-elect Nisa Leung to serve as a director until the 2023 annual general meeting of shareholders and until her successor is duly elected and qualified, subject to her earlier resignation or removal. | Management | For | For | |||||
O6 | An ordinary resolution to re-elect William Lis to serve as a director until the 2023 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal. | Management | For | For | |||||
O7 | An ordinary resolution to re-elect Scott Morrison to serve as a director until the 2023 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal. | Management | For | For | |||||
O8 | An ordinary resolution to re-elect Lonnie Moulder to serve as a director until the 2023 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal. | Management | For | For | |||||
O9 | An ordinary resolution to re-elect Peter Wirth to serve as a director until the 2023 annual general meeting of shareholders and until his successor is duly elected and qualified, subject to his earlier resignation or removal. | Management | For | For | |||||
S10 | A special resolution to adopt the Sixth Amended and Restated Memorandum and Articles of Association of the Company in the form annexed hereto as Appendix A as described in this Proxy Statement, conditioned on and subject to the dual-primary listing of the Company on the Main Board of The Stock Exchange of Hong Kong Limited. | Management | For | For | |||||
O11 | An ordinary resolution to approve the Zai Lab Limited 2022 Equity Incentive Plan, conditioned on and subject to the dual- primary listing of the Company on the Main Board of The Stock Exchange of Hong Kong Limited becoming effective. | Management | For | For | |||||
O12 | An ordinary resolution to ratify the appointment of KPMG LLP (“KPMG”) as the Company’s independent registered public...(due to space limits, see proxy material for full proposal). | Management | For | For | |||||
O13 | An ordinary resolution, within the parameters of Rule 13.36 of the HK Listing Rules, to approve the granting of a share issue...(due to space limits, see proxy material for full proposal). | Management | For | For | |||||
O14 | An ordinary resolution to approve, on an advisory basis, the compensation of our named executive officers, as disclosed in this Proxy Statement. | Management | For | For | |||||
O15 | An ordinary resolution to hold an advisory vote on the frequency of future advisory votes on the compensation of our named executive officers. | Management | 3 Years | For |
ZIMMER BIOMET HOLDINGS, INC.
Security | 98956P102 | Meeting Type | Annual |
Ticker Symbol | ZBH | Meeting Date | 13-May-2022 |
Record Date | 14-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Director: Christopher B. Begley | Management | For | For | |||||
1B. | Election of Director: Betsy J. Bernard | Management | For | For | |||||
1C. | Election of Director: Michael J. Farrell | Management | For | For | |||||
1D. | Election of Director: Robert A. Hagemann | Management | For | For | |||||
1E. | Election of Director: Bryan C. Hanson | Management | For | For | |||||
1F. | Election of Director: Arthur J. Higgins | Management | For | For | |||||
1G. | Election of Director: Maria Teresa Hilado | Management | For | For | |||||
1H. | Election of Director: Syed Jafry | Management | For | For | |||||
1I. | Election of Director: Sreelakshmi Kolli | Management | For | For | |||||
1J. | Election of Director: Michael W. Michelson | Management | For | For | |||||
2. | Ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2022. | Management | For | For | |||||
3. | Approve, on a non-binding advisory basis, named executive officer compensation (“Say on Pay”). | Management | For | For |
ZOETIS, INC.
Security | 98978V103 | Meeting Type | Annual |
Ticker Symbol | ZTS | Meeting Date | 19-May-2022 |
Record Date | 25-Mar-2022 |
Item | Proposal | Proposed by | Vote | For/Against Management | |||||
1A. | Election of Director: Paul M. Bisaro | Management | For | For | |||||
1B. | Election of Director: Frank A. D’Amelio | Management | For | For | |||||
1C. | Election of Director: Michael B. McCallister | Management | For | For | |||||
2. | Advisory vote to approve our executive compensation. | Management | For | For | |||||
3. | Approval of an Amendment and Restatement of our 2013 Equity and Incentive Plan. | Management | For | For | |||||
4. | Ratification of appointment of KPMG LLP as our independent registered public accounting firm for 2022. | Management | For | For | |||||
5. | Approval of an amendment to our Restated Certificate of Incorporation to eliminate supermajority voting provisions and certain provisions related to Pfizer Inc. | Management | For | For | |||||
6. | Approval of an amendment to our Restated Certificate of Incorporation to declassify the Board of Directors. | Management | For | For |
SIGNATURES
Pursuant to the requirements of the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
(Registrant) | Tekla Healthcare Investors | |||
By (Signature and Title)* | ||||
/s/ Daniel R. Omstead | ||||
(Daniel R. Omstead, President) | ||||
Date | 8/19/22 | |||
*Print the name and title of each signing officer under his or her signature.
2